View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Feb. 15, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	AMN HEALTHCARE SERVICES INC
Entity Central Index Key	0001142750
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		47,724,130
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,892,328,216

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 10,622	$ 9,576
Accounts receivable, net of allowances of $11,376 and $7,691 at December 31, 2016 and 2015, respectively	341,977	277,996
Accounts receivable, subcontractor	49,233	50,807
Prepaid expenses	14,189	13,526
Other current assets	34,607	23,723
Total current assets	450,628	375,628
Restricted cash, cash equivalents and investments	31,287	27,352
Fixed assets, net of accumulated depreciation of $84,865 and $76,680 at December 31, 2016 and 2015, respectively	59,954	50,134
Other assets	57,534	47,569
Goodwill	341,754	204,779
Intangible assets, net of accumulated amortization of $72,057 and $53,747 at December 31, 2016 and 2015, respectively	245,724	174,970
Total assets	1,186,881	880,432
Current liabilities:
Accounts payable and accrued expenses	137,512	118,822
Accrued compensation and benefits	107,993	83,701
Current portion of revolving credit facility	0	30,000
Current portion of notes payable	3,750	7,500
Deferred revenue	8,924	5,620
Other current liabilities	16,611	5,374
Total current liabilities	274,790	251,017
Revolving credit facility	0	52,500
Notes payable, less unamortized fees	359,192	128,490
Deferred income taxes, net	21,420	22,431
Other long-term liabilities	82,096	78,134
Total liabilities	737,498	532,572
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 10,000 shares authorized; none issued and outstanding at December 31, 2016 and 2015	0	0
Common stock, $0.01 par value; 200,000 shares authorized; 48,055 issued and 47,612 shares issued and outstanding, respectively, at December 31, 2016 and 47,709 shares issued and outstanding at December 31, 2015	481	477
Additional paid-in capital	452,491	443,733
Treasury stock, at cost (443 and 0 shares at December 31, 2016 and 2015, respectively)	(13,261)	0
Retained earnings (accumulated deficit)	9,671	(96,167)
Accumulated other comprehensive income (loss)	1	(183)
Total stockholders’ equity	449,383	347,860
Total liabilities and stockholders’ equity	$ 1,186,881	$ 880,432

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 11,376	$ 7,691
Accumulated depreciation	84,865	76,680
Accumulated amortization	$ 72,057	$ 53,747
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	48,055,000	47,709,000
Common stock, shares outstanding	47,612,000	47,709,000
Treasury Stock, shares	443,000	0

Consolidated Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Revenue	$ 1,902,225	$ 1,463,065	$ 1,036,027
Cost of revenue	1,282,501	993,702	719,910
Gross profit	619,724	469,363	316,117
Operating expenses:
Selling, general and administrative	398,472	319,531	232,221
Depreciation and amortization	29,620	20,953	15,993
Total operating expenses	428,092	340,484	248,214
Income from operations	191,632	128,879	67,903
Interest expense, net (including loss on debt extinguishment of $3,113 for the year ended December 31, 2014), and other	15,465	7,790	9,237
Income before income taxes	176,167	121,089	58,666
Income tax expense	70,329	39,198	25,449
Net income	105,838	81,891	33,217
Other comprehensive income:
Foreign currency translation	267	75	142
Unrealized gain (loss) on cash flow hedge, net of income taxes	(83)	98	0
Other comprehensive income	184	173	142
Comprehensive income	$ 106,022	$ 82,064	$ 33,359
Net income per common share:
Basic (in dollars per share)	$ 2.21	$ 1.72	$ 0.71
Diluted (in dollars per share)	$ 2.15	$ 1.68	$ 0.69
Weighted average common shares outstanding:
Basic (shares)	47,946	47,525	46,504
Diluted (shares)	49,267	48,843	48,086

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Loss on debt extinguishment	$ 0	$ 0	$ 3,113

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Gain (Loss)
Balance, shares at Dec. 31, 2013		46,011		0
Balance at Dec. 31, 2013	$ 217,742	$ 460	$ 429,055	$ 0	$ (211,275)	$ (498)
Statement of Stockholders' Equity [Roll Forward]
Equity awards vested and exercised, net of shares withheld for payroll taxes, shares		628
Equity awards vested and exercised, net of shares withheld for payroll taxes	(2,655)	$ 6	(2,661)
Excess income tax benefit from equity awards vested and exercised	978		978
Share-based compensation	7,157		7,157
Comprehensive income	33,359				33,217	142
Balance, shares at Dec. 31, 2014		46,639		0
Balance at Dec. 31, 2014	256,581	$ 466	434,529	$ 0	(178,058)	(356)
Statement of Stockholders' Equity [Roll Forward]
Equity awards vested and exercised, net of shares withheld for payroll taxes, shares		1,070
Equity awards vested and exercised, net of shares withheld for payroll taxes	(8,245)	$ 11	(8,256)
Excess income tax benefit from equity awards vested and exercised	7,176		7,176
Share-based compensation	10,284		10,284
Comprehensive income	82,064				81,891	173
Balance, shares at Dec. 31, 2015		47,709		0
Balance at Dec. 31, 2015	347,860	$ 477	443,733	$ 0	(96,167)	(183)
Statement of Stockholders' Equity [Roll Forward]
Equity awards vested and exercised, net of shares withheld for payroll taxes, shares		346
Equity awards vested and exercised, net of shares withheld for payroll taxes	(5,781)	$ 4	(5,785)
Excess income tax benefit from equity awards vested and exercised	3,144		3,144
Share-based compensation	11,399		11,399
Comprehensive income	106,022				105,838	184
Repurchase of common stock into treasury (in shares)				(443)
Repurchase of common stock into treasury				$ (13,261)
Balance, shares at Dec. 31, 2016		48,055		443
Balance at Dec. 31, 2016	$ 449,383	$ 481	$ 452,491	$ (13,261)	$ 9,671	$ 1

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income	$ 105,838	$ 81,891	$ 33,217
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	29,620	20,953	15,993
Non-cash interest expense and other	2,416	1,934	1,392
Change in fair value of contingent consideration	(24)	(330)	0
Increase in allowances for doubtful accounts and sales credits	12,008	6,684	4,393
Provision for deferred income taxes	(9,424)	12,677	11,779
Share-based compensation	11,399	10,284	7,157
Excess tax benefit from equity awards vested and exercised	(3,351)	(7,449)	(1,819)
Loss on disposal or sale of fixed assets	69	4	60
Loss on debt extinguishment	0	0	3,113
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable	(58,700)	(75,653)	(41,958)
Accounts receivable, subcontractor	1,542	(22,365)	(10,172)
Income taxes receivable	6,469	7,867	768
Prepaid expenses	(455)	(2,915)	(1,933)
Other current assets	(13,938)	(5,409)	1,920
Other assets	(3,562)	(4,785)	(268)
Accounts payable and accrued expenses	17,705	29,611	6,125
Accrued compensation and benefits	19,142	11,888	11,515
Other liabilities	8,147	(2,103)	(4,488)
Deferred revenue	732	1,313	(114)
Restricted cash, cash equivalents and investments balance	6,218	(7,784)	(9,002)
Net cash provided by operating activities	131,851	56,313	27,678
Cash flows from investing activities:
Purchase and development of fixed assets	(21,956)	(27,010)	(19,134)
Purchase of investments	(13,152)	0	0
Proceeds from maturity of investments	2,000	0	0
Change in restricted cash, cash equivalents and investments balance	999	0	12,550
Equity method investment	0	(1,000)	(5,000)
Payments to fund deferred compensation plan	(6,911)	(3,004)	(2,174)
Cash paid for acquisitions, net of cash received	(216,494)	(84,081)	(14,470)
Cash paid for working capital adjustments and holdback liability for prior year acquisitions	(1,848)	(990)	0
Net cash used in investing activities	(257,362)	(116,085)	(28,228)
Cash flows from financing activities:
Capital lease repayments	(7)	(4)	(529)
Payments on term loans	(167,813)	(7,500)	(155,245)
Proceeds from term loan	75,000	0	150,000
Payments on revolving credit facility	(206,500)	(25,000)	(39,500)
Proceeds from revolving credit facility	124,000	89,500	47,500
Proceeds from senior notes	325,000	0	0
Repurchase of common stock	(13,261)	0	0
Payment of financing costs	(6,561)	0	(3,488)
Earn-out payment for prior acquisition	(900)	0	0
Payment on reduction of derivative contract	(238)	0	0
Proceeds from exercise of equity awards	0	3,663	1,792
Cash paid for shares withheld for taxes	(5,781)	(11,908)	(4,448)
Excess tax benefit from equity awards vested and exercised	3,351	7,449	1,819
Net cash provided by (used in) financing activities	126,290	56,200	(2,099)
Effect of exchange rate changes on cash	267	75	142
Net change in cash and cash equivalents	1,046	(3,497)	(2,507)
Cash and cash equivalents at beginning of year	9,576	13,073	15,580
Cash and cash equivalents at end of year	10,622	9,576	13,073
Supplemental disclosures of cash flow information:
Cash paid for interest (net of $174, $264 and $123 capitalized in 2016, 2015 and 2014, respectively)	8,057	5,806	4,599
Cash paid for income taxes	73,366	33,132	17,880
Acquisitions:
Fair value of tangible assets acquired in acquisitions, net of cash received	18,703	26,771	1,631
Goodwill	136,101	50,227	9,750
Intangible assets	89,064	34,237	9,960
Liabilities and deferred revenue assumed	(21,474)	(22,954)	(3,821)
Holdback provision	(1,830)	(1,500)	(1,650)
Earn-out liabilities	(4,070)	(2,700)	(1,400)
Net cash paid for acquisitions	216,494	84,081	14,470
Supplemental disclosures of non-cash investing and financing activities:
Purchase of fixed assets recorded in accounts payable and accrued expenses	$ 2,134	$ 3,337	$ 4,618

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Cash Flows [Abstract]
Interest capitalized	$ 174	$ 264	$ 123

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

(a) General

AMN Healthcare Services, Inc. was incorporated in Delaware on November 10, 1997. AMN Healthcare Services, Inc. and its subsidiaries (collectively, the “Company”) provide healthcare workforce solutions and staffing services at acute and sub-acute care hospitals and other healthcare facilities throughout the United States.

(b) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to asset impairment, accruals for self-insurance and compensation and related benefits, contingencies and litigation, and income taxes. The Company bases these estimates on the information that is currently available and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents include currency on hand, deposits with financial institutions and highly liquid investments.

(e) Restricted Cash, Cash Equivalents and Investments

Restricted cash and cash equivalents primarily represent cash and money market funds on deposit with financial institutions and investments represents commercial paper that serves as collateral for the Company’s outstanding letters of credit and captive insurance subsidiary claim payments. See Note (4), “Fair Value Measurement” and Note (8), “Notes Payable and Credit Agreement” for additional information.

(f) Fixed Assets

The Company records furniture, equipment, leasehold improvements and internal-use software at cost less accumulated amortization and depreciation. The Company records equipment acquired under capital leases at the present value of the future minimum lease payments. The Company capitalizes major additions and improvements, and it expenses maintenance and repairs when incurred. The Company calculates depreciation on furniture, equipment and technology and software using the straight-line method based on the estimated useful lives of the related assets (three to ten years). The Company amortizes leasehold improvements and equipment obtained under capital leases over the shorter of the term of the lease or their estimated useful lives. The Company includes depreciation of equipment obtained under capital leases with depreciation expense in the accompanying consolidated financial statements.

The Company capitalizes costs it incurs to develop internal-use software during the application development stage. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. The Company also capitalizes costs of significant upgrades and enhancements that result in additional functionality, whereas it expenses as incurred costs for maintenance and minor upgrades and enhancements. The Company amortizes capitalized costs using the straight-line method over three to ten years once the software is ready for its intended use.

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the future undiscounted net cash flows that are expected to be generated by the asset group. If such asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. The Company reports assets to be disposed of at the lower of the carrying amount or fair value less costs to sell.

(g) Goodwill

The Company records as goodwill the portion of the purchase price that exceeds the fair value of net assets of entities acquired. The Company evaluates goodwill annually for impairment at the reporting unit level and whenever circumstances occur indicating that goodwill may be impaired. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines that it is more likely than not that the fair value of the reporting unit is greater than its carrying amount, the quantitative impairment test is unnecessary. The performance of the quantitative impairment test involves a two-step process. The first step of the test involves comparing the fair value of the Company’s reporting units with the reporting unit’s carrying amount, including goodwill. The Company generally determines the fair value of its reporting units using a combination of the income approach (using discounted future cash flows) and the market valuation approach. If the carrying amount of a Company’s reporting unit exceeds its fair value, the Company performs the second step of the test to determine the amount of impairment loss. The second step of the test involves comparing the implied fair value of the Company’s reporting unit’s goodwill with the carrying amount of that goodwill. The amount by which the carrying value of the goodwill exceeds its implied fair value, if any, is recognized as an impairment loss.

(h) Intangible Assets

Intangible assets consist of identifiable intangible assets acquired through acquisitions. Identifiable intangible assets include tradenames and trademarks, customer relationships, non-compete agreements, staffing databases and acquired technology. The Company amortizes intangible assets, other than tradenames and trademarks with an indefinite life, using the straight-line method over their useful lives. The Company amortizes non-compete agreements using the straight-line method over the lives of the related agreements. The Company reviews for impairment intangible assets with estimable useful lives whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

The Company does not amortize indefinite-lived tradenames and trademarks and instead reviews them for impairment annually. The Company may first perform a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company determines that it is more likely than not that the indefinite-lived intangible asset is not impaired, no quantitative fair value measurement is necessary. If a quantitative fair value measurement calculation is required for an indefinite-lived intangible asset, the Company compares its fair value with its carrying amount. If the carrying amount exceeds the fair value, the Company records the excess as an impairment loss.

(i) Insurance Reserves

The Company maintains an accrual for professional liability that is included in accounts payable and accrued expenses and other long-term liabilities in the consolidated balance sheets. The expense is included in the selling, general and administrative expenses in the consolidated statement of comprehensive income. The Company determines the adequacy of this accrual by evaluating its historical experience and trends, loss reserves established by the Company’s insurance carriers, management and third-party administrators, and independent actuarial studies. The Company obtains actuarial studies on a semi-annual basis that use the Company’s actual claims data and industry data to assist the Company in determining the adequacy of its reserves each year. For periods between the actuarial studies, the Company records its accruals based on loss rates provided in the most recent actuarial study and management’s review of loss history. In November 2012, the Company established a captive insurance subsidiary, which provides coverage, on an occurrence basis, for professional liability within its nurse and allied solutions segment. Liabilities include provisions for estimated losses incurred but not yet reported (“IBNR”), as well as provisions for known claims. IBNR reserve estimates involve the use of assumptions that are primarily based upon historical loss experience, industry data and other actuarial assumptions. The Company maintains excess insurance coverage through a commercial carrier for losses above the per occurrence retention.

The Company maintains an accrual for workers compensation, which is included in accrued compensation and benefits and other long-term liabilities in the consolidated balance sheets. The expense relating to healthcare professionals is included in cost of revenue, while the expense relating to corporate employees is included in the selling, general and administrative expenses in the consolidated statement of comprehensive income. The Company determines the adequacy of this accrual by evaluating its historical experience and trends, loss reserves established by the Company’s insurance carriers and third-party administrators, and independent actuarial studies. The Company obtains actuarial studies on a semi-annual basis that use the Company’s payroll and historical claims data, as well as industry data, to determine the appropriate reserve for both reported claims and IBNR claims for each policy year. For periods between the actuarial studies, the Company records its accruals based on loss rates provided in the most recent actuarial study.

(j) Revenue Recognition

Revenue consists of fees earned from the temporary and permanent placement of healthcare professionals and executives as well as from the Company’s software-as-a-service (SaaS)-based technologies, including its vendor management systems (VMS) and its scheduling software. Revenue from temporary staffing services is recognized as the services are rendered by the healthcare professional. Under the Company’s managed services program arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own pool of healthcare professionals along with those of third-party subcontractors. When the Company uses subcontractors, revenue is recorded net of the related subcontractor’s expense. Revenue from recruitment and permanent placement services is recognized as the services are provided and upon successful placements. The Company’s SaaS-based revenue is recognized ratably over the applicable arrangement’s service period. Fees billed in advance of being earned are recorded as deferred revenue.

(k) Accounts Receivable

The Company records accounts receivable at the invoiced amount. Accounts receivable are non-interest bearing. The Company maintains an allowance for doubtful accounts based on the Company’s historical write-off experience and an assessment of its customers’ financial conditions. The Company also maintains a sales allowance to reserve for potential credits issued to customers, which is based on the Company’s historical experience. The Company has not experienced material bad debts or sales adjustments during the past three years.

(l) Concentration of Credit Risk

The majority of the Company’s business activity is with hospitals located throughout the United States. Credit is extended based on the evaluation of each entity’s financial condition. One customer within the Company’s nurse and allied solutions segment comprised approximately 11%, 11% and 10% of the consolidated revenue of the Company for the fiscal years ended December 31, 2016, 2015 and 2014, respectively.

The Company’s cash and cash equivalents and restricted cash, cash equivalents and investment accounts are financial instruments that are exposed to concentration of credit risk. The Company maintains most of its cash, cash equivalents and investment balances with high-credit quality and federally insured institutions. However, restricted cash equivalents and investment balances may be invested in a non-federally insured money market account and commercial paper. As of December 31, 2016 and 2015, there were $31,287 and $27,352, respectively, of restricted cash, cash equivalents and investments, a portion of which was invested in a non-federally insured money market fund and commercial paper. See Note (4), “Fair Value Measurement,” for additional information.

(m) Income Taxes

The Company records income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period the changes are enacted. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making this assessment. The Company recognizes the effect of income tax positions only if it is more likely than not that such positions will be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

(n) Fair Value of Financial Instruments

The carrying amounts of the Company’s cash equivalents and restricted cash equivalents and investments approximate their respective fair values due to the short-term nature and liquidity of these financial instruments. The carrying amounts of the Company’s Notes (as defined in Note (3) below), Term Loans and Revolver (as defined in Note (8) below) approximate their fair values. As it relates to the Term Loans and Revolver, the Company amended its credit facilities in January 2016 to increase the capacity of the Revolver and to secure an additional term loan, and the variable interest rate under the Revolver and the Term Loans (LIBOR plus 1.50% to 2.25% or a base rate plus a spread of 0.50% to 1.25%, at the Company’s option) has remained unchanged since the amendment. As it relates to the Notes issued in October 2016, they have a fixed rate of 5.125% and there have been no changes in available rates for similar debt since the date of issuance. See Note (8), “Notes Payable and Credit Agreement,” for additional information. The fair value of the long-term portion of the Company’s insurance accruals cannot be estimated because the Company cannot reasonably determine the timing of future payments.

(o) Share-Based Compensation

The Company accounts for its share-based employee compensation plans by expensing the estimated fair value of share-based awards on a straight-line basis over the requisite employee service period, which is the vesting period. Restricted stock units (“RSUs”) typically vest at the end of a three-year vesting period, however, 33% of the awards may vest on the 13th month anniversary of the grant date and 34% on the second anniversary of the grant date if certain performance targets are met. Share-based compensation cost of RSUs is measured by the market value of the Company’s common stock on the date of grant, and the Company records share-based compensation expense only for those awards that are expected to vest. Performance restricted stock units (“PRSUs”) primarily consist of PRSUs that contain a performance condition dependent on the Company’s adjusted EBITDA margin during the third year of the three-year vesting period, with a range of 0% to 175% of the target amount granted to be issued under the award. Share-based compensation cost for these PRSUs is measured by the market value of the Company’s common stock on the date of grant, and the amount recognized is adjusted for estimated achievement of the performance conditions. A limited amount of PRSUs contain a market condition dependent upon the Company’s relative and absolute total shareholder return over a three-year period, with a range of 0% to 175% of the target amount granted to be issued under the award. Share-based compensation cost for these PRSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the performance conditions.

(p) Net Income per Common Share

Share-based awards to purchase 16, 9 and 298 shares of common stock for the years ended December 31, 2016, 2015 and 2014, respectively, were not included in the calculation of diluted net income per common share because the effect of these instruments was anti-dilutive.

The following table sets forth the computation of basic and diluted net income per common share for the years ended December 31, 2016, 2015 and 2014, respectively:



	Years Ended December 31,
	2016		2015		2014
Net income	$	105,838	$	81,891	$	33,217

Net income per common share - basic	$	2.21	$	1.72	$	0.71
Net income per common share - diluted	2.15		1.68		0.69

Weighted average common shares outstanding - basic	47,946		47,525		46,504
Plus dilutive effect of potential common shares	1,321		1,318		1,582
Weighted average common shares outstanding - diluted	49,267		48,843		48,086

(q) Segment Information

The Company’s operating segments are identified in the same manner as they are reported internally and used by the Company’s chief operating decision maker for the purpose of evaluating performance and allocating resources. Effective as of January 1, 2016, the Company modified its reportable segments. The Company previously utilized three reportable segments, which it identified as follows: (1) nurse and allied healthcare staffing, (2) locum tenens staffing, and (3) physician permanent placement services. In light of the Company’s acquisitions over the past several years as well as its transition to a provider of healthcare workforce solutions, the Company’s management renamed its three reportable segments and also placed several of its business lines that were in the nurse and allied healthcare staffing segment into a different segment to better reflect how the business is evaluated by the chief operating decision maker. As of January 1, 2016, the Company began to disclose the following three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. The nurse and allied solutions segment consists of the Company’s nurse, allied, local and labor disruption and rapid response staffing businesses. The locum tenens solutions segment consists of the Company’s locum tenens staffing business. The other workforce solutions segment consists of the following Company businesses (i) physician permanent placement services, (ii) healthcare interim leadership staffing and executive search services, (iii) vendor management systems, (iv) recruitment process outsourcing, (v) education, (vi) medical coding and related consulting, and (vii) workforce optimization services.

The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

The following table, which includes reclassified prior period data to conform to the new segment reporting structure, provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes:



	Years Ended December 31,
	2016		2015		2014
Revenue
Nurse and allied solutions	$	1,185,095	$	953,253	$	674,055
Locum tenens solutions	424,242		385,091		296,166
Other workforce solutions	292,888		124,721		65,806
	$	1,902,225	$	1,463,065	$	1,036,027
Segment operating income
Nurse and allied solutions	$	161,779	$	123,969	$	82,498
Locum tenens solutions	58,757		48,011		30,985
Other workforce solutions	77,450		40,390		14,566
	297,986		212,370		128,049
Unallocated corporate overhead	65,335		52,254		36,996
Depreciation and amortization	29,620		20,953		15,993
Share-based compensation	11,399		10,284		7,157
Interest expense, net (including loss on debt extinguishment of $3,113 for the year ended December 31, 2014), and other	15,465		7,790		9,237
Income before income taxes	$	176,167	$	121,089	$	58,666

(r) Reclassifications

Certain reclassifications have been made to certain of the prior years’ notes to the consolidated financial statements to conform to the current year presentation.

(s) Recently Adopted Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU 2015-05, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement.” This standard provides guidance about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the software license element of the arrangement should be accounted for by the customer consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company adopted this pronouncement prospectively beginning January 1, 2016, and the adoption did not have a material effect on the Company’s consolidated financial statements.

In September 2015, the FASB issued ASU 2015-16, “Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments.” This standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The standard requires that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The standard also requires an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The Company adopted this pronouncement prospectively beginning January 1, 2016, and the adoption did not have a material effect on the Company’s consolidated financial statements.

Business Combinations

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Business Combinations

As set forth below, the Company completed seven acquisitions from January 1, 2014 through December 31, 2016. The Company accounted for each acquisition using the acquisition method of accounting. Accordingly, it recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For each acquisition, the Company did not incur any material acquisition-related costs.

Peak Provider Solutions Acquisition

On June 3, 2016, the Company completed its acquisition of Peak Provider Solutions (“Peak”), which provides remote medical coding and consulting solutions to hospitals and physician medical groups nationwide. The addition of Peak has expanded the Company’s workforce solutions and enables the Company to offer services in coding diagnosis and procedure codes, which is critical to clinical quality reporting and the financial health of healthcare organizations. The initial purchase price of $52,125 included (1) $51,645 cash consideration paid upon acquisition, funded through cash-on-hand, net of cash received, and borrowings under the Company’s Revolver, and (2) a contingent earn-out payment of up to $3,000 with an estimated fair value of $480 as of the acquisition date. The contingent earn-out payment is based on the operating results of Peak for the year ended December 31, 2016. As the acquisition’s operations are not considered material, pro forma information is not provided. The results of Peak have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2016, an additional $275 of cash consideration was paid to the selling shareholders for the final working capital settlement.

The preliminary allocation of the $52,400 purchase price, which included the additional cash consideration paid for the final working capital settlement, consisted of (1) $5,658 of fair value of tangible assets acquired, (2) $9,305 of liabilities assumed, (3) $19,220 of identified intangible assets, and (4) $36,827 of goodwill, none of which is deductible for tax purposes. The fair value of intangible assets primarily includes $7,600 of trademarks and $11,500 of customer relationships with a weighted average useful life of approximately thirteen years.

HealthSource Global Staffing Acquisition

On January 11, 2016, the Company completed its acquisition of HealthSource Global Staffing (“HSG”), which provides labor disruption and rapid response staffing. The acquisition enabled the Company to expand its service lines to include labor disruption services. The initial purchase price of $8,511 included (1) $2,799 cash consideration paid upon acquisition, funded through cash-on-hand, net of cash received, and settlement of the pre-existing relationship between AMN and HSG, (2) $2,122 cash holdback for potential indemnification claims, and (3) a tiered contingent earn-out payment of up to $4,000 with an estimated fair value of $3,590 as of the acquisition date. The contingent earn-out payment is comprised of (A) up to $2,000 based on the operating results of HSG for the year ended December 31, 2016, and (B) up to $2,000 based on the operating results of HSG for the year ending December 31, 2017. As the acquisition is not considered material, pro forma information is not provided. The results of HSG have been included in the Company’s nurse and allied solutions segment since the date of acquisition. During the third quarter of 2016, the final working capital settlement resulted in $292 due from the selling shareholders to the Company, which was settled through a reduction to a cash holdback.

The allocation of the $8,219 purchase price, which was reduced by the final working capital settlement, consisted of (1) $1,025 of fair value of tangible assets acquired, (2) $4,897 of liabilities assumed, (3) $3,944 of identified intangible assets, and (4) $8,147 of goodwill, none of which is deductible for tax purposes. The intangible assets include the fair value of trademarks, customer relationships, staffing databases, and covenants not to compete with a weighted average useful life of approximately eight years.

B.E. Smith Acquisition

On January 4, 2016, the Company completed its acquisition of B.E. Smith (“BES”), a full-service healthcare interim leadership placement and executive search firm, for $162,232 in cash, net of cash received, and settlement of the pre-existing relationship between AMN and BES. BES places interim leaders and executives across all healthcare settings, including acute care hospitals, academic medical and children’s hospitals, physician practices, and post-acute care providers. The acquisition provides the Company additional access to healthcare executives and enhances its integrated services to hospitals, health systems, and other healthcare facilities across the nation. To help finance the acquisition, the Company entered into the First Amendment to the Credit Agreement (the “First Amendment”), which provided $125,000 of additional available borrowings to the Company. The First Amendment is more fully described in Note (8), “Notes Payable and Credit Agreement.” The results of BES have been included in the Company’s other workforce solutions segment since the date of acquisition. During the second quarter of 2016, $524 was returned to the Company for the final working capital settlement.

The allocation of the $161,708 purchase price, which was reduced by the final working capital settlement, consisted of (1) $11,953 of fair value of tangible assets acquired, (2) $7,272 of liabilities assumed, (3) $65,900 of identified intangible assets, and (4) $91,127 of goodwill, most of which is deductible for tax purposes. The intangible assets acquired have a weighted average useful life of approximately fifteen years. The following table summarizes the fair value and useful life of each intangible asset acquired:



		Fair Value		Useful Life
				(in years)
Identifiable intangible assets
	Tradenames and Trademarks	$	26,300	20
	Customer Relationships	25,700		12
	Staffing Database	13,000		10
	Non-Compete Agreements	900		5
		$	65,900

Approximately $108,459 of revenue and $16,491 of income before income taxes of BES were included in the consolidated statement of comprehensive income for the year ended December 31, 2016. The following summary presents unaudited pro forma consolidated results of operations of the Company for the year ended December 31, 2015 as if the BES acquisition had occurred on January 1, 2015, which gives effect to certain adjustments, including the reduction of compensation expense related to non-recurring executive salary expense and the addition of acquisition-related costs and amortization of intangible assets. The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as of the date indicated, nor is it necessarily indicative of the Company’s future operating results.



	Year Ended December 31,
(Unaudited)	2015
Revenue	$	1,556,729
Income from operations	$	132,023
Net income	$	80,114
Net income per common share:
Basic	$	1.69
Diluted	$	1.64

MillicanSolutions Acquisition

On October 5, 2015, the Company acquired MillicanSolutions (“Millican”), a physician and executive leadership search firm. The total purchase price of $3,985 included (1) $2,985 cash consideration paid upon acquisition, funded by cash-on-hand, (2) $500 paid in December 2016, and (3) $500 to be paid on December 31, 2017. The acquisition enhances the Company’s ability to respond to the specialized leadership needs within academic pediatrics and children’s medical centers and expands its expertise in serving academic medical centers and teaching hospitals in physician and leadership search. As the acquisition is not considered material, pro forma information is not provided. The results of operations of Millican have been included in the Company’s other workforce solutions segment since the date of acquisition.

The allocation of the $3,985 purchase price consisted of (1) $261 of fair value of tangible assets acquired, (2) $287 of liabilities assumed, (3) $645 of identified intangible assets and (4) $3,366 of goodwill, a portion of which is deductible for tax purposes. The intangible assets include the fair value of tradenames and trademarks, staffing databases, customer relationships, and a covenant not to compete. The weighted average useful life of the acquired intangible assets subject to amortization is approximately five years.

The First String Healthcare Acquisition

On September 15, 2015, the Company completed its acquisition of The First String Healthcare (“TFS”), a leading provider of interim staffing and permanent placement of nurse leaders and executives. The total purchase price of $7,653 included (1) $4,453 cash consideration paid upon acquisition, funded by cash-on-hand, net of cash received, (2) $500 to be paid on the first anniversary of the acquisition date, which was paid in September 2016, and (3) a contingent earn-out with a fair value of $2,700 as of the acquisition date. Also, the purchase agreement included an additional $1,000 payment to be paid on the second anniversary of the acquisition date conditioned upon, subject to certain exceptions, continued employment of the selling shareholders, which is being recorded as compensation expense for post-combination services. The acquisition enhances the Company’s capabilities to provide interim and permanent nursing leadership. As the acquisition is not considered material, pro forma information is not provided. The results of operations of TFS are included in the other workforce solutions segment since the date of acquisition.

The acquisition agreement provides for a tiered contingent earn-out payment of up to $4,000, of which (1) $1,000 was paid to the sellers in March 2016 based on the operating results of TFS for the twelve months ended December 31, 2015, and (2) up to $3,000 may be paid in 2017 based on the operating results of TFS for the twelve months ended December 31, 2016. The allocation of the $7,653 purchase price consisted of (A) $919 of fair value of tangible assets acquired, (B) $891 of liabilities assumed, (C) $3,373 of identified intangible assets and (D) $4,252 of goodwill, which is deductible for tax purposes. The intangible assets include the fair value of tradenames and trademarks, customer relationships, a staffing database, and covenants not to compete. The weighted average useful life of the acquired intangible assets subject to amortization is approximately seven years.

Onward Healthcare Acquisition

On January 7, 2015, the Company completed its acquisition of Onward Healthcare, including its two wholly-owned subsidiaries, Locum Leaders and Medefis (collectively, “OH”), for approximately $76,643 in cash, funded by cash-on-hand and borrowings under the Company’s Revolver. Onward Healthcare is a national nurse and allied healthcare staffing firm, Locum Leaders is a national locum tenens provider, and Medefis is a provider of a SaaS-based vendor management system for healthcare facilities. The acquisition helps the Company to expand its service lines and its supply and placement capabilities of healthcare professionals to its clients. The results of Onward Healthcare are included in the Company’s nurse and allied solutions segment, the results of Locum Leaders are included in the Company’s locum tenens solutions segment, and the results of Medefis are included in the Company’s other workforce solutions segment, in each case, since the date of acquisition.

The allocation of the $76,643 purchase price consisted of (1) $25,216 of fair value of tangible assets acquired (including $21,313 of accounts receivable), (2) $22,275 of liabilities assumed (including $11,113 of accounts payable and accrued expenses), (3) $30,219 of identified intangible assets, and (4) $43,483 of goodwill, a portion of which is deductible for tax purposes. The intangible assets include the fair value of tradenames and trademarks, customer relationships, staffing database, acquired technologies, and non-compete agreements. The weighted average useful life of the acquired intangible assets is approximately eleven years. The following table summarizes the fair value and useful life of each intangible asset acquired:



		Fair Value		Useful Life
				(in years)
Identifiable intangible assets
	Tradenames and Trademarks	$	8,100	3 - 15
	Customer Relationships	17,600		10 - 15
	Staffing Database	2,600		5
	Acquired Technologies	1,700		8
	Non-Compete Agreements	219		2
		$	30,219

Of the $43,483 allocated to goodwill, $23,032, $5,241 and $15,210 were allocated to the Company’s nurse and allied solutions, locum tenens solutions and other workforce solutions segments, respectively.

Avantas Acquisition

On December 22, 2014, the Company acquired Avantas, LLC (“Avantas”), a provider of clinical workforce management services, including its proprietary SaaS-based scheduling technology. The initial purchase price of $17,520 included (1) $14,470 cash consideration paid at acquisition, funded through cash-on-hand and borrowings under the Company’s Revolver, (2) $1,650 cash holdback for potential indemnification claims and (3) a tiered contingent earn-out of up to $8,500 based on the operating performance of Avantas during the 12-month period ended June 30, 2016, with an estimated fair value at acquisition of $1,400. During the year ended December 31, 2015, the Company paid an additional $165 to the selling shareholders for a working capital adjustment. The acquisition expanded the Company’s ability to provide workforce optimization services. The results of operations of Avantas are included in the Company’s other workforce solutions segment since the date of acquisition.

The allocation of the total $17,685 purchase price (which gives effect to the $165 working capital adjustment on the initial purchase price) consisted of (1) $1,631 of fair value of tangible assets acquired, (2) $3,821 of liabilities and deferred revenue assumed, (3) $9,960 of identified intangible assets, including tradenames and trademarks, customer relationships and acquired technologies with a weighted average useful life of approximately fourteen years and (4) $9,915 of goodwill, a portion of which is deductible for tax purposes.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Derivative Instruments	12 Months Ended
Derivative Instruments	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative Instruments In April 2015, the Company entered into an interest rate swap agreement to minimize its exposure to interest rate fluctuations on $100,000 of its outstanding variable rate debt under one of its Term Loans whereby the Company pays a fixed rate of 0.983% per annum and receives a variable rate equal to floating one-month LIBOR. The agreement expires on March 30, 2018. In connection with the Company’s issuance of $325,000 aggregate principal amount of 5.125% Senior Notes due 2024 (the “Notes”) and the use of a portion of the proceeds thereof to repay $138,438 of certain indebtedness under the Term Loans on October 3, 2016, the Company reduced the interest rate swap notional amount to $40,000 in the fourth quarter of 2016. As a result, $238 was recorded to interest expense reflecting the settlement amount with the counterparty to reduce the notional amount. See additional information in Note (8), “Notes Payable and Credit Agreement.” At December 31, 2016, the interest rate swap had a fair value of $24, which is included in other assets in the consolidated balance sheet as of December 31, 2016. At December 31, 2015, the interest rate swap agreement had a fair value of $165, which is included in other assets in the audited consolidated balance sheet as of December 31, 2015. The Company has formally documented the hedging relationship and accounts for this arrangement as a cash flow hedge. The Company recognizes all derivatives on the balance sheet at fair value based on quotes from an independent pricing service. Gains or losses resulting from changes in the values of the arrangement are recorded in other comprehensive income, net of tax, until the hedged item is recognized in earnings. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the derivative instrument that is used in the hedging transaction is highly effective in offsetting changes in fair values or cash flows of the hedged item. When it is determined that a derivative instrument is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the Company discontinues hedge accounting prospectively and recognizes subsequent changes in market value in earnings.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurement

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurement

Fair value represents the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would conduct a transaction, in addition to the assumptions that market participants would use when pricing the related assets or liabilities, including non-performance risk.

A three-level hierarchy prioritizes the inputs to valuation techniques used to measure fair value and requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of the fair value hierarchy are as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and Liabilities Measured on a Recurring Basis

The Company’s restricted cash equivalents that serve as collateral for the Company’s outstanding letters of credit typically consist of money market funds that are measured at fair value based on quoted prices, which are Level 1 inputs.

As of December 31, 2016, the Company’s restricted cash equivalents and investments that serve as collateral for the Company’s captive insurance company primarily consist of commercial paper that is measured at observable market prices for identical securities that are traded in less active markets, which are Level 2 inputs. Of the $25,610 commercial paper as of December 31, 2016, $11,152 had original maturities greater than three months, which were considered available for sale securities. The Company did not have commercial paper as of December 31, 2015.

The Company’s interest rate swap is measured at fair value using a discounted cash flow analysis that includes the contractual terms, including the period to maturity, and Level 2 observable market-based inputs, including interest rate curves. The fair value of the swap is determined by netting the discounted future fixed cash receipts payments and the discounted expected variable cash receipts. The variable cash receipts are based on an expectation of future interest rates (forward curves) derived from observable market interest rate yield curves. The valuation also considers credit risk adjustments that are necessary to reflect the probability of default by the counterparty or the Company, which are considered Level 3 inputs; however, as of December 31, 2016, the credit risk adjustments, including nonperformance risk, were considered insignificant to the total fair value of the interest rate swap.

The Company’s contingent consideration liabilities are measured at fair value using probability-weighted discounted cash flow analysis for the acquired companies, which are Level 3 inputs.

The following tables present information about assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:



	Fair Value Measurements as of December 31, 2016
Assets (Liabilities)	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	4,627		$	4,627	$	—	$	—
Commercial paper	25,610			—		25,610		—
Interest rate swap asset	24			—		24		—
Acquisition contingent consideration liabilities	(6,816		)	—		—		(6,816		)



	Fair Value Measurements as of December 31, 2015
Assets (Liabilities)	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	5,627		$	5,627	$	—	$	—
Interest rate swap asset	165			—		165		—
Acquisition contingent consideration liabilities	(3,770		)	—		—		(3,770		)

The following table sets forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:



	Years Ended December 31,
	2016			2015
Balance as of January 1,	$	(3,770	)	$	(1,400	)
Contingent consideration earn-out liability from TFS acquisition on September 15, 2015	—			(2,700		)
Settlement of TFS earn-out for year ended December 31, 2015	1,000			—
Contingent consideration earn-out liability from HSG acquisition on January 11, 2016	(3,590		)	—
Change in fair value of contingent consideration earn-out liability from Avantas acquisition	660			740
Change in fair value of contingent consideration earn-out liability from TFS acquisition	(890		)	(410		)
Change in fair value of contingent consideration earn-out liability from HSG acquisition	(226		)	—
Contingent consideration earn-out liability from Peak acquisition on June 3, 2016	(480		)	—
Change in fair value of contingent consideration earn-out liability from Peak acquisition	480			—
Balance as of December 31,	$	(6,816	)	$	(3,770	)

Assets Measured on a Non-Recurring Basis

The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to its goodwill, indefinite-lived intangible assets, long-lived assets and equity method investment.

The Company evaluates goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill or indefinite-lived intangible assets might be impaired. The Company determines the fair value of its reporting units based on a combination of inputs, including the market capitalization of the Company, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. The Company determines the fair value of its indefinite-lived intangible assets using the income approach (relief-from-royalty method) based on Level 3 inputs.

There were no impairment charges recorded during the three years ended December 31, 2016 requiring such measurements.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Identifiable Intangible Assets

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Identifiable Intangible Assets

As of December 31, 2016 and 2015, the Company had the following acquired intangible assets:



	As of December 31, 2016							As of December 31, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangible assets subject to amortization:
Staffing databases	$	19,826	$	(5,633	)	$	14,193	$	6,333	$	(3,592	)	$	2,741
Customer relationships	136,759		(50,309		)	86,450		96,829		(40,076		)	56,753
Tradenames and trademarks	61,369		(12,139		)	49,230		26,853		(7,718		)	19,135
Non-compete agreements	1,697		(678		)	1,019		572		(276		)	296
Acquired technology	8,730		(3,298		)	5,432		8,730		(2,085		)	6,645
	$	228,381	$	(72,057	)	$	156,324	$	139,317	$	(53,747	)	$	85,570

Intangible assets not subject to amortization: tradenames and trademarks						$	89,400						$	89,400
						$	245,724						$	174,970

Aggregate amortization expense for intangible assets was $18,310 and $11,784 for the years ended December 31, 2016 and 2015, respectively. Based on the current amount of intangibles subject to amortization, the estimated amortization expense as of December 31, 2016 is as follows:



	Amount
Year ending December 31, 2017	$	18,628
Year ending December 31, 2018	17,555
Year ending December 31, 2019	16,827
Year ending December 31, 2020	13,889
Year ending December 31, 2021	11,899
Thereafter	77,526
	$	156,324

The following table summarizes the activity related to the carrying value of goodwill by reportable segment:



	Nurse and Allied Solutions		Locum Tenens Solutions		Other Workforce Solutions		Total
Balance, January 1, 2015	$	73,127	$	14,502	$	66,758	$	154,387
Goodwill adjustment for Avantas acquisition	—		—		165		165
Goodwill from OH acquisition	22,182		5,241		15,210		42,633
Goodwill from TFS acquisition	—		—		4,228		4,228
Goodwill from Millican acquisition	—		—		3,366		3,366
Balance, December 31, 2015	95,309		19,743		89,727		204,779
Goodwill from BES acquisition	—		—		91,127		91,127
Goodwill from HSG acquisition	8,147		—		—		8,147
Goodwill from Peak acquisition	—		—		36,827		36,827
Goodwill adjustment for Onward acquisition	850		—		—		850
Goodwill adjustment for TFS acquisition	—		—		24		24
Balance, December 31, 2016	$	104,306	$	19,743	$	217,705	$	341,754
Accumulated impairment loss as of December 31, 2015 and 2016	$	154,444	$	53,940	$	6,555	$	214,939

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Balance Sheet Details

12 Months Ended

Dec. 31, 2016

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Details

The consolidated balance sheets detail is as follows as of December 31, 2016 and 2015:



	As of December 31,
	2016			2015
Other current assets:
Restricted cash	20,271			11,995
Income taxes receivable	361			3,687
Other	13,975			8,041
Other current assets	$	34,607		$	23,723

Fixed assets:
Furniture and equipment	$	25,582		$	23,380
Technology and software	112,405			97,962
Leasehold improvements	6,832			5,472
	144,819			126,814
Accumulated depreciation	(84,865		)	(76,680		)
Fixed assets, net	$	59,954		$	50,134

Accounts payable and accrued expenses:
Trade accounts payable	$	33,392		$	28,761
Subcontractor payable	51,973			56,177
Accrued expenses	37,251			24,502
Professional liability reserve	10,254			7,962
Other	4,642			1,420
Accounts payable and accrued expenses	$	137,512		$	118,822

Accrued compensation and benefits:
Accrued payroll	$	30,917		$	21,058
Accrued bonuses and commissions	26,992			24,476
Accrued travel expense	2,972			2,740
Accrued health insurance reserve	3,189			3,225
Accrued workers compensation reserve	8,406			7,701
Deferred compensation	32,690			23,044
Other	2,827			1,457
Accrued compensation and benefits	$	107,993		$	83,701

Other current liabilities:
Acquisition related liabilities	6,921			3,485
Other	9,690			1,889
Other current liabilities	$	16,611		$	5,374

Other long-term liabilities:
Workers compensation reserve	$	18,708		$	16,899
Professional liability reserve	37,338			37,369
Deferred rent	13,274			11,826
Unrecognized tax benefits	8,464			8,081
Other	4,312			3,959
Other long-term liabilities	$	82,096		$	78,134

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

The provision for income taxes from operations for the years ended December 31, 2016, 2015 and 2014 consists of the following:



	Years Ended December 31,
	2016			2015		2014
Current income taxes:
Federal	$	68,312		$	22,552	$	10,787
State	11,441			3,969		2,883
Total	79,753			26,521		13,670
Deferred income taxes:
Federal	(9,115		)	8,896		10,430
State	(309		)	3,781		1,349
Total	(9,424		)	12,677		11,779
Provision for income taxes from operations	$	70,329		$	39,198	$	25,449

Total income tax expense for the years ended December 31, 2016, 2015 and 2014 was allocated as follows:



	Years Ended December 31,
	2016			2015			2014
Provision for income taxes from operations	$	70,329		$	39,198		$	25,449
Shareholders’ equity, for compensation expense for tax purposes in excess of amounts recognized for financial reporting purposes	(3,144		)	(7,176		)	(978		)
	$	67,185		$	32,022		$	24,471

The Company’s income tax expense differs from the amount that would have resulted from applying the federal statutory rate of 35% to pretax income from operations because of the effect of the following items during the years ended December 31, 2016, 2015 and 2014:



	Years Ended December 31,
	2016			2015			2014
Tax expense at federal statutory rate	$	61,658		$	42,381		$	20,533
State taxes, net of federal benefit	7,597			5,260			2,551
Non-deductible expenses	3,656			3,505			1,816
Unrecognized tax benefit	379			(11,464		)	971
Other, net	(2,961		)	(484		)	(422		)
Income tax expense from operations	$	70,329		$	39,198		$	25,449

The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are presented below as of the years ended December 31, 2016 and 2015:



	Years Ended December 31,
	2016			2015
Deferred tax assets:
Stock compensation	$	11,954		$	10,170
Deferred compensation	13,079			9,153
Accrued expenses	35,499			24,932
Deferred rent	5,492			4,885
Net operating losses	5,756			8,809
Other	6,576			4,872
Total deferred tax assets	$	78,356		$	62,821
Deferred tax liabilities:
Intangibles	$	(78,201	)	$	(67,574	)
Fixed assets	(18,847		)	(15,155		)
Other	(2,545		)	(1,480		)
Total deferred tax liabilities	$	(99,593	)	$	(84,209	)
Valuation allowance	$	(183	)	$	(1,043	)
Net deferred tax liabilities	$	(21,420	)	$	(22,431	)

The deferred tax benefit of $9,424 shown above is different from the change in net deferred tax liabilities primarily due to deferred tax balances recorded through acquisitions in 2016.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management believes it is more likely than not that the Company will realize the benefits of its deferred tax assets, net of the recorded valuation allowance.

The amount of federal NOL carryforward that is available for use in years subsequent to December 31, 2016 is $13,920, which is set to expire by 2029. The amount of state NOL carryforward that is available for use in years subsequent to December 31, 2016 is $16,674, which is set to expire at various dates between 2017 and 2032.

A summary of the changes in the amount of unrecognized tax benefits (excluding interest and penalties) for 2016, 2015 and 2014 is as follows:



	2016			2015			2014
Beginning balance of unrecognized tax benefits	$	6,537		$	22,890		$	22,573
Additions based on tax positions related to the current year	—			—			317
Additions based on tax positions of prior years	868			395			—
Reductions due to lapse of applicable statute of limitation	(563		)	(214		)	—
Settlements	—			(16,534		)	—
Ending balance of unrecognized tax benefits	$	6,842		$	6,537		$	22,890

At December 31, 2016, if recognized, approximately $6,752 would affect the effective tax rate (including interest).

The Company recognizes interest related to unrecognized tax benefits in income tax expense. The Company had approximately $1,622, $1,544 and $5,815 of accrued interest related to unrecognized tax benefits at December 31, 2016, 2015 and 2014, respectively. The amount of interest expense (benefit) recognized in 2016, 2015 and 2014 was $78, $(4,272) and $1,211, respectively.

The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2016, the Company is no longer subject to state, local or foreign examinations by tax authorities for tax years before 2006, and the Company is no longer subject to U.S. federal income or payroll tax examinations for tax years before 2011. The Company’s tax years 2007, 2008, 2009 and 2010 had been under audit by the Internal Revenue Service (“IRS”) for several years and in 2014, the IRS issued the Company its Revenue Agent Report (“RAR”) and an Employment Tax Examination Report (“ETER”). The RAR proposed adjustments to the Company’s taxable income for 2007-2010 and net operating loss carryforwards for 2005 and 2006, resulting from the proposed disallowance of certain per diems paid to the Company’s healthcare professionals, and the ETER proposed assessments for additional payroll tax liabilities and penalties for tax years 2009 and 2010 related to the Company’s treatment of certain non-taxable per diem allowances and travel benefits. The positions in the RAR and ETER were mutually exclusive, and contained multiple tax positions, some of which were contrary to each other. The Company filed a Protest Letter for both the RAR and ETER positions in 2014 and the Company received a final determination from the IRS in July 2015 on both the RAR adjustments and ETER assessments, effectively settling these audits with the IRS for $7,200 (including interest) during the third quarter of 2015. As a result of the settlement, the Company recorded federal income tax benefits of approximately $12,200 during the quarter ended September 30, 2015, state income tax benefits (net of federal tax impact) of $568 for the year ended December 31, 2016, and expects to record the state income tax benefits (net of federal tax impact) of approximately $1,200 by fiscal year 2019, when the various state statutes are projected to lapse.

The IRS conducted and completed a separate audit of the Company’s 2011 and 2012 tax years that focused on income and employment tax issues similar to those raised in the 2007 through 2010 examination. The IRS completed its audit during the quarter ended March 31, 2015, and issued its RAR and ETER to the Company with proposed adjustments to the Company’s taxable income for 2011 and 2012 and net operating loss carryforwards from 2010 and assessments for additional payroll tax liabilities and penalties for 2011 and 2012 related to the Company’s treatment of certain non-taxable per diem allowances and travel benefits. The positions in the RAR and ETER for the 2011 and 2012 years are mutually exclusive and contain multiple tax positions, some of which are contrary to each other. The Company filed a Protest Letter for both the RAR and ETER in April 2015 and the matter is currently at IRS Appeals. The Company recently held its first meeting with the IRS Appeals office and will continue to meet with the IRS Appeals office during the next twelve months. The Company cannot predict with certainty the timing of a resolution of such matter. The IRS began an audit of the Company’s 2013 tax year during the quarter ended June 30, 2015. The Company believes its reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years. Notwithstanding the foregoing, the Company could adjust its provision for income taxes and contingent tax liability based on future developments.

Notes Payable and Credit Agreement

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Notes Payable and Credit Agreement

(a) The Company’s Credit Agreement and Related Credit Facilities

The Company is party to a credit agreement (as amended to date, the “Credit Agreement”) with several lenders in respect of three credit facilities (the “Credit Facilities”), including (A) a $275,000 revolver facility (the “Revolver”), which includes a $40,000 sublimit for the issuance of letters of credit and a $20,000 sublimit for swingline loans, (B) a $150,000 secured term loan facility (the “Original Term Loan”) and (C) a $75,000 secured term loan facility (the “Second Term Loan,” and together with the Original Term Loan, the “Term Loans”). The Company used the proceeds from the Second Term Loan, which it obtained (along with an increase of $50,000 to the Revolver) under the First Amendment, and draw downs of the Revolver to complete its acquisitions of BES and Peak, as more fully described in Note (2), “Business Combinations.” The maturity dates of the Revolver and the Original Term Loan, on the one hand, and the Second Term Loan, on the other hand, are April 18, 2019 and January 4, 2021, respectively. The Company fully repaid all amounts under the Original Term Loan in 2016.

On September 19, 2016, the Company entered into another amendment to the Credit Agreement (the “Second Amendment”), which, among other things, permits the Company to increase the commitments that may be obtained under the Credit Agreement by the amount of certain prepayments made thereunder. Accordingly, the Credit Agreement provides that the Company may from time to time obtain an increase in the Revolver or obtain additional term loans or both in an aggregate principal amount not to exceed $125,000 plus the amount of certain prepayments of Credit Facilities (including $138,438 of prepayments of the Term Loans made by the Company on October 3, 2016) subject to, among other conditions, the arrangement of additional commitments with financial institutions reasonably acceptable to the Company and the administrative agent.

The Revolver carries an unused fee of 0.25% to 0.35% per annum and each standby letter of credit issued under the Revolver is subject to a letter of credit fee ranging from 1.50% to 2.25% per annum of the average daily maximum amount available to be drawn under the standby letter of credit, in each case, depending on the Company’s consolidated leverage ratio, as calculated quarterly in accordance with the Credit Agreement. The Second Term Loan is subject to amortization of principal of 5.00% per year of the original loan amount, which is $3,750 per annum, and payable in equal quarterly installments. Borrowings under the Second Term Loan and Revolver bear interest at floating rates, at the Company’s option, based upon either LIBOR plus a spread of 1.50% to 2.25% or a base rate plus a spread of 0.50% to 1.25%. The applicable spread is determined quarterly based upon the Company’s consolidated leverage ratio. The interest rate for the outstanding Second Term Loan was 2.5% on a LIBOR basis as of December 31, 2016.

The Credit Agreement contains various customary affirmative and negative covenants, including restrictions on incurrence of additional indebtedness, declaration and payment of dividends, dispositions of assets, consolidation into another entity, and allowable investments. Additionally, there are financial covenants based on the Company’s consolidated leverage ratio and interest coverage ratio as calculated in accordance with the Credit Agreement. The payment obligations under the Credit Agreement may be accelerated upon the occurrence of defined events of default. Additionally, the Credit Agreement no longer requires (as was originally set forth in the original Credit Agreement) the Company to make mandatory prepayments under any of the credit facilities provided thereunder with the proceeds of extraordinary receipts and excess cash flow when certain financial conditions were present. The Credit Facilities are secured by substantially all of the assets of the Company and the common stock or equity interests of its domestic subsidiaries.

In connection with obtaining the original two Credit Facilities (i.e., the Revolver and the Original Term Loan) in April 2014, the Company incurred $3,488 in fees paid to lenders and other third parties, which were capitalized and are amortized to interest expense over the term of the original two Credit Facilities. In addition, the Company wrote off $3,113 of unamortized financing fees and original issue discount, which was recorded as loss on debt extinguishment in the accompanying consolidated statement of comprehensive income for the year ended December 31, 2014. In connection with the First Amendment, the Company incurred $632 in fees paid to lenders and other third parties, of which $448 was capitalized and amortized to interest expense on a pro rata basis over the remaining term of the Revolver and the term of the Second Term Loan and the remaining amount was recorded as interest expense during the year ended December 31, 2016. The Company incurred de minimis costs in connection with the Second Amendment.

The Revolver is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes of the Company. At December 31, 2016, with $10,752 of outstanding letters of credit collateralized by the Revolver, there was $264,248 of available credit under the Revolver.

(b) The Company’s 5.125% Senior Notes Due 2024

On October 3, 2016, the Company completed the issuance and sale of $325,000 aggregate principal amount of the Notes, which mature on October 1, 2024. Interest on the Notes is fixed at 5.125% and payable semi-annually in arrears on April 1 and October 1 of each year, commencing April 1, 2017. With the proceeds from the Notes and cash generated from operations, the Company (1) repaid $131,250 of Original Term Loan indebtedness, (2) repaid $7,188 of existing Second Term Loan indebtedness, (3) repaid $182,500 under the Revolver, and (4) paid $6,113 of fees and expenses related to the issuance and sale of the Notes, which were recorded as a reduction of the notes payable balance and are being amortized to interest expense over the term of the Notes.

The indenture governing the Notes contains covenants that, among other things, restrict the ability of the Company to:

•sell assets,

•pay dividends or make other distributions on capital stock or make payments in respect of subordinated indebtedness,

•make investments,

•incur additional indebtedness or issue preferred stock,

•create, or permit to exist, certain liens,

•enter into agreements that restrict dividends or other payments from restricted subsidiaries,

•consolidate, merge or transfer all or substantially all of its assets,

•engage in transactions with affiliates, and

•create unrestricted subsidiaries.

These covenants are subject to a number of important exceptions and qualifications. The indenture governing the Notes contains affirmative covenants and events of default that are customary for indentures governing high yield securities. The Notes and the related guarantees thereof are not subject to any registration rights agreements.

Outstanding debt balances as of December 31, 2016 and 2015 consisted of the following:



	As of December 31,
	2016			2015
Revolver	$	—		$	82,500
Original Term Loan	—			136,875
Second Term Loan	44,063			—
Notes	325,000			—
Total debt outstanding	369,063			219,375
Less unamortized discount	(6,121		)	(885		)
Less current portion of notes payable and Revolver	(3,750		)	(37,500		)
Long-term portion of notes payable and Revolver	$	359,192		$	180,990

Annual principal maturities of the Second Term Loan and the Notes as of December 31, 2016 are as follows:



Year ending December 31, 2017	$	3,750
Year ending December 31, 2018	3,750
Year ending December 31, 2019	3,750
Year ending December 31, 2020	3,750
Year ending December 31, 2021	29,063
Thereafter	325,000
	$	369,063

(d) Letters of Credit

At December 31, 2016, the Company maintained outstanding standby letters of credit totaling $15,379 as collateral in relation to its professional liability insurance agreements, workers compensation insurance agreements, and a corporate office lease agreement. Of the $15,379 outstanding letters of credit, the Company has collateralized $4,627 in cash and cash equivalents and the remaining amount has been collateralized by the Revolver. Outstanding standby letters of credit at December 31, 2015 totaled $15,788.

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	Retirement Plans The Company maintains the AMN Services 401(k) Retirement Savings Plan (the “AMN Plan”), which the Company believes complies with the IRC Section 401(k) provisions. The AMN Plan covers all employees that meet certain age and other eligibility requirements. An annual discretionary matching contribution is determined by the Compensation and Stock Plan Committee of the Board of Directors each year. Employer contribution expenses incurred under the AMN Plan were $5,010, $1,618 and $544 for the years ended December 31, 2016, 2015 and 2014, respectively. The Company has a deferred compensation plan for certain executives and key employees (the “Plan”). The Plan is not intended to be tax qualified and is an unfunded plan. The Plan is composed of deferred compensation and all related income and losses attributable thereto. Discretionary matching contributions to the Plan are made that vest incrementally so that the employee is fully vested in the match following five years of employment with the Company. Under the Plan, participants can defer up to 80% of their base salary, 90% of their bonus and 100% of their vested RSUs or vested PRSUs. An annual discretionary matching contribution is determined by the Compensation and Stock Plan Committee of the Board of Directors each year. Employer contributions under the Plan were $3,032, $974 and $595 for the years ended December 31, 2016, 2015 and 2014, respectively. In connection with the administration of the Plan, the Company has purchased company-owned life insurance policies insuring the lives of certain officers and key employees. The cash surrender value of these policies was $32,190 and $23,005 at December 31, 2016 and 2015, respectively. The cash surrender value of these insurance policies is included in other assets in the consolidated balance sheets.

Capital Stock	12 Months Ended
Capital Stock	Dec. 31, 2016
Equity [Abstract]
Capital Stock	Capital Stock (a) Preferred Stock The Company has 10,000 shares of preferred stock authorized for issuance in one or more series (including preferred stock designated as Series A Conditional Convertible Preferred Stock), at a par value of $0.01 per share. At December 31, 2016 and 2015, no shares of preferred stock were outstanding. (b) Treasury Stock On November 1, 2016, the Company’s Board of Directors approved a share repurchase program under which the Company may repurchase up to $150,000 of its outstanding common stock. The amount and timing of the purchases will depend on a number of factors including the price of the Company’s shares, trading volume, Company performance, Company liquidity, general economic and market conditions and other factors that the Company’s management believes are relevant. The share repurchase program does not require the purchase of any minimum number of shares and may be suspended or discontinued at any time. The Company intends to make all repurchases and to administer the plan in accordance with applicable laws and regulatory guidelines, including Rule 10b-18 of the Exchange Act, and in compliance with its debt instruments. Repurchases may be made from cash on hand, free cash flow generated from the Company’s business or from the Company’s Revolver. Repurchases may be made from time to time through open market purchases or privately negotiated transactions. Repurchases may also be made pursuant to one or more plans established pursuant to Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading restrictions. During the fourth quarter of 2016, the Company repurchased 443 shares of its common stock at an average price of $29.88 per share, resulting in an aggregate purchase price of $13,261.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Share-Based Compensation

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

(a) Equity Award Plans

Stock Option Plan

The Company established a stock option plan (the “Stock Option Plan”) to provide a means to attract and retain employees. 4,178 options were authorized for issuance to be granted under the Stock Option Plan. On April 12, 2006, 371 shares of common stock reserved for future issuance under the Stock Option Plan were rolled into the Equity Plan, which is discussed below. The Stock Option Plan has expired and no further equity awards have been granted from the Stock Option Plan since 2005. As of December 31, 2016 and 2015, no equity awards were outstanding under it.

Equity Plan

The Company established the AMN Healthcare Equity Plan (as amended or amended and restated from time to time, the “Equity Plan”), which has been approved by the Company’s stockholders. At the time of the Equity Plan’s original adoption in 2006, equity awards, based on the Company’s common stock, could be issued for a maximum of 723 shares plus the number of shares of common stock underlying any grants under the Stock Option Plan (under which there are no longer any outstanding awards) that were forfeited, canceled or terminated (other than by exercise) from and after the effective date of the Equity Plan. Pursuant to the Equity Plan, stock options and stock appreciation rights (“SARs”) granted have a maximum contractual life of ten years and have exercise prices that will be determined at the time of grant, which will be no less than fair market value of the underlying common stock on the date of grant. Any shares to be issued under the Equity Plan will be issued by the Company from authorized but unissued common stock or shares of common stock reacquired by the Company. On April 18, 2007, April 9, 2009 and April 18, 2012, the Company amended the Equity Plan, with stockholder approval, to increase the number of shares authorized under the Equity Plan by 3,000, 1,850 and 2,400, respectively. At December 31, 2016 and 2015, respectively, 1,933 and 2,128 shares of common stock were reserved for future grants under the Equity Plan.

Other Plans

From time to time, the Company grants, and has granted, key employees inducement awards outside of the Equity Plan (collectively, “Other Plans”), which have consisted of SARs, options or RSUs. Although these awards are not made under the Equity Plan, the key terms and conditions of the grant are typically the same as equity awards made under the Equity Plan.

Additionally, in February 2014, the Company established the 2014 Employment Inducement Plan, which reserves for issuance 200 shares of common stock for prospective employees of the Company. As of December 31, 2016, 200 shares of common stock remained available for future grants under the 2014 Employment Inducement Plan.

(b) Share-Based Compensation

Restricted Stock Units

RSUs and PRSUs (subject to a PRSU being earned) granted under the Equity Plan generally entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company’s common stock. The following table summarizes RSU and PRSU activity for non-vested awards for the years ended December 31, 2016, 2015 and 2014:



	Number of Shares		Weighted Average Grant Date Fair Value per Share
Unvested at January 1, 2014	1,637		$	9.73
Granted—RSUs	361		$	13.76
Granted—PRSUs (1)	535		$	14.97
Vested	(838	)	$	8.63
Canceled/forfeited/expired	(120	)	$	12.16
Unvested at December 31, 2014	1,575		$	11.95
Granted—RSUs	203		$	22.43
Granted—PRSUs (1)	616		$	13.58
Vested	(1,081	)	$	9.13
Canceled/forfeited/expired	(76	)	$	15.45
Unvested at December 31, 2015	1,237		$	16.73
Granted—RSUs	180		$	32.65
Granted—PRSUs (1)	361		$	20.88
Vested	(641	)	$	14.90
Canceled/forfeited/expired	(62	)	$	22.57
Unvested at December 31, 2016	1,075		$	22.14

(1) PRSUs granted included both the PRSUs granted during the year at the target amount and the additional shares of prior period granted PRSUs vested during the year in excess of the target shares.

As of December 31, 2016, there was $11,136 unrecognized compensation cost related to non-vested RSUs and PRSUs. The Company expects to recognize such cost over a period of 1.8 years. As of December 31, 2016 and 2015, the aggregate intrinsic value of the RSUs and PRSUs outstanding was $41,317 and $38,400, respectively.

Stock Options and SARs

Stock options entitle the holder to purchase, at the end of a vesting period, a specified number of shares of the Company’s common stock at a price per share set at the date of grant. SARs entitle the holder to receive, at the end of a vesting period, shares of the Company’s common stock equal in value to the difference between the exercise price of the SAR, which is set at the date of grant, and the fair market value of the Company’s common stock on the date of exercise.

A summary of stock option and SAR activity under the Stock Option Plan and the Equity Plan and Other Plans are as follows:



	Stock Option Plan				Equity Plan and Other Plans
	Number Outstanding		Weighted- Average Exercise Price per Share		Number Outstanding		Weighted- Average Exercise Price per Share
Outstanding at December 31, 2013	589		$	14.92	1,096		$	10.78
Granted	—		$	—	—		$	—
Exercised	(117	)	$	14.86	(142	)	$	11.53
Canceled/forfeited/expired	(227	)	$	14.94	(6	)	$	19.69
Outstanding at December 31, 2014	245		$	14.93	948		$	10.61
Granted	—		$	—	—		$	—
Exercised	(245	)	$	14.93	(615	)	$	10.79
Canceled/forfeited/expired	—		$	—	(1	)	$	24.95
Outstanding at December 31, 2015	—		$	—	332		$	10.26
Granted	—		$	—	—		$	—
Exercised	—		$	—	(44	)	$	13.69
Canceled/forfeited/expired	—		$	—	(2	)	$	18.03
Outstanding at December 31, 2016	—		$	—	286		$	9.67
Vested and expected to vest at December 31, 2016	—		$	—	286		$	9.67
Exercisable at December 31, 2016	—		$	—	286		$	9.67

As of December 31, 2016, all SARs were fully vested, and there were no stock options outstanding. The total intrinsic value of stock options and SARs exercised was $877, $10,505 and $770 for 2016, 2015 and 2014, respectively. At December 31, 2016 and 2015, the total intrinsic value of stock options and SARs outstanding and exercisable was $8,247 and $7,013, respectively.

Share-Based Compensation

Total share-based compensation expense for the years ended December 31, 2016, 2015 and 2014 was as follows:



	Years Ended December 31,
	2016			2015			2014
Share-based employee compensation, before tax	$	11,399		$	10,284		$	7,157
Related income tax benefits	(4,423		)	(3,990		)	(2,783		)
Share-based employee compensation, net of tax	$	6,976		$	6,294		$	4,374

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

(a) Legal

From time to time, the Company is involved in various lawsuits, claims, investigations, and proceedings that arise in the

ordinary course of business. These matters typically relate to professional liability, tax, payroll, contract, competitor disputes and employee-related matters and include individual and collective lawsuits, as well as inquiries and investigations by governmental agencies regarding the Company’s employment practices. Additionally, some of the Company’s clients may also become subject to claims, governmental inquiries and investigations, and legal actions relating to services provided by the Company’s healthcare professionals. Depending upon the particular facts and circumstances, the Company may also be subject to indemnification obligations under its contracts with such clients relating to these matters. The Company records a liability when management believes an adverse outcome from a loss contingency is both probable and the amount, or a range, can be reasonably estimated. Significant judgment is required to determine both probability of loss and the estimated amount. The Company reviews its loss contingencies at least quarterly and adjusts its accruals and/or disclosures to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, or other new information, as deemed necessary. During the first quarter of 2014, the Company completed the settlement of a wage and hour class action (and a related action) for an immaterial amount. The most significant matters for which the Company has established loss contingencies are class actions related to wage and hour claims. Management currently believes the probable loss related to these wage and hour claims is not significant and the amount accrued by the Company for such claims is not material as of December 31, 2016. However, losses ultimately incurred for such claims could materially differ from amounts already accrued by the Company.

With regards to outstanding loss contingencies as of December 31, 2016, which are included in accounts payable and accrued expenses in the consolidated balance sheet, the Company believes that such matters will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.

(b) Leases

The Company leases certain office facilities and equipment under various operating leases. The Company recognizes rent expense on a straight-line basis over the lease term. Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) as of December 31, 2016 are as follows:



	Operating Leases
Years ending December 31,
2017	$	17,194
2018	17,037
2019	16,400
2020	15,886
2021	16,019
Thereafter	82,675
Total minimum lease payments	$	165,211

Rent expense under operating leases was $18,793, $15,940, and $14,136 for the years ended December 31, 2016, 2015 and 2014, respectively.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)



	Year Ended December 31, 2016
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(In thousands, except per share data)
Revenue	$	468,002	$	473,729	$	472,636	$	487,858	$	1,902,225
Gross profit	$	151,898	$	154,753	$	154,467	$	158,606	$	619,724
Net income	$	25,869	$	26,322	$	27,296	$	26,351	$	105,838
Net income per share from:
Basic	$	0.54	$	0.55	$	0.57	$	0.55	$	2.21
Diluted	$	0.53	$	0.53	$	0.55	$	0.54	$	2.15



	Year Ended December 31, 2015
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(In thousands, except per share data)
Revenue	$	327,510	$	350,144	$	382,859	$	402,552	$	1,463,065
Gross profit	$	101,432	$	110,118	$	126,009	$	131,804	$	469,363
Net income	$	12,209	$	15,870	$	33,647	$	20,165	$	81,891
Net income per share from:
Basic	$	0.26	$	0.33	$	0.71	$	0.42	$	1.72
Diluted	$	0.25	$	0.32	$	0.69	$	0.41	$	1.68

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to asset impairment, accruals for self-insurance and compensation and related benefits, contingencies and litigation, and income taxes. The Company bases these estimates on the information that is currently available and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents include currency on hand, deposits with financial institutions and highly liquid investments.
Restricted Cash, Cash Equivalents, and Investments	Restricted Cash, Cash Equivalents and Investments Restricted cash and cash equivalents primarily represent cash and money market funds on deposit with financial institutions and investments represents commercial paper that serves as collateral for the Company’s outstanding letters of credit and captive insurance subsidiary claim payments.
Fixed Assets	Fixed Assets The Company records furniture, equipment, leasehold improvements and internal-use software at cost less accumulated amortization and depreciation. The Company records equipment acquired under capital leases at the present value of the future minimum lease payments. The Company capitalizes major additions and improvements, and it expenses maintenance and repairs when incurred. The Company calculates depreciation on furniture, equipment and technology and software using the straight-line method based on the estimated useful lives of the related assets (three to ten years). The Company amortizes leasehold improvements and equipment obtained under capital leases over the shorter of the term of the lease or their estimated useful lives. The Company includes depreciation of equipment obtained under capital leases with depreciation expense in the accompanying consolidated financial statements. The Company capitalizes costs it incurs to develop internal-use software during the application development stage. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. The Company also capitalizes costs of significant upgrades and enhancements that result in additional functionality, whereas it expenses as incurred costs for maintenance and minor upgrades and enhancements. The Company amortizes capitalized costs using the straight-line method over three to ten years once the software is ready for its intended use. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the future undiscounted net cash flows that are expected to be generated by the asset group. If such asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. The Company reports assets to be disposed of at the lower of the carrying amount or fair value less costs to sell.
Goodwill	Goodwill The Company records as goodwill the portion of the purchase price that exceeds the fair value of net assets of entities acquired. The Company evaluates goodwill annually for impairment at the reporting unit level and whenever circumstances occur indicating that goodwill may be impaired. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines that it is more likely than not that the fair value of the reporting unit is greater than its carrying amount, the quantitative impairment test is unnecessary. The performance of the quantitative impairment test involves a two-step process. The first step of the test involves comparing the fair value of the Company’s reporting units with the reporting unit’s carrying amount, including goodwill. The Company generally determines the fair value of its reporting units using a combination of the income approach (using discounted future cash flows) and the market valuation approach. If the carrying amount of a Company’s reporting unit exceeds its fair value, the Company performs the second step of the test to determine the amount of impairment loss. The second step of the test involves comparing the implied fair value of the Company’s reporting unit’s goodwill with the carrying amount of that goodwill. The amount by which the carrying value of the goodwill exceeds its implied fair value, if any, is recognized as an impairment loss.
Intangible Assets	Intangible Assets Intangible assets consist of identifiable intangible assets acquired through acquisitions. Identifiable intangible assets include tradenames and trademarks, customer relationships, non-compete agreements, staffing databases and acquired technology. The Company amortizes intangible assets, other than tradenames and trademarks with an indefinite life, using the straight-line method over their useful lives. The Company amortizes non-compete agreements using the straight-line method over the lives of the related agreements. The Company reviews for impairment intangible assets with estimable useful lives whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company does not amortize indefinite-lived tradenames and trademarks and instead reviews them for impairment annually. The Company may first perform a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company determines that it is more likely than not that the indefinite-lived intangible asset is not impaired, no quantitative fair value measurement is necessary. If a quantitative fair value measurement calculation is required for an indefinite-lived intangible asset, the Company compares its fair value with its carrying amount. If the carrying amount exceeds the fair value, the Company records the excess as an impairment loss.
Insurance Reserves	Insurance Reserves The Company maintains an accrual for professional liability that is included in accounts payable and accrued expenses and other long-term liabilities in the consolidated balance sheets. The expense is included in the selling, general and administrative expenses in the consolidated statement of comprehensive income. The Company determines the adequacy of this accrual by evaluating its historical experience and trends, loss reserves established by the Company’s insurance carriers, management and third-party administrators, and independent actuarial studies. The Company obtains actuarial studies on a semi-annual basis that use the Company’s actual claims data and industry data to assist the Company in determining the adequacy of its reserves each year. For periods between the actuarial studies, the Company records its accruals based on loss rates provided in the most recent actuarial study and management’s review of loss history. In November 2012, the Company established a captive insurance subsidiary, which provides coverage, on an occurrence basis, for professional liability within its nurse and allied solutions segment. Liabilities include provisions for estimated losses incurred but not yet reported (“IBNR”), as well as provisions for known claims. IBNR reserve estimates involve the use of assumptions that are primarily based upon historical loss experience, industry data and other actuarial assumptions. The Company maintains excess insurance coverage through a commercial carrier for losses above the per occurrence retention. The Company maintains an accrual for workers compensation, which is included in accrued compensation and benefits and other long-term liabilities in the consolidated balance sheets. The expense relating to healthcare professionals is included in cost of revenue, while the expense relating to corporate employees is included in the selling, general and administrative expenses in the consolidated statement of comprehensive income. The Company determines the adequacy of this accrual by evaluating its historical experience and trends, loss reserves established by the Company’s insurance carriers and third-party administrators, and independent actuarial studies. The Company obtains actuarial studies on a semi-annual basis that use the Company’s payroll and historical claims data, as well as industry data, to determine the appropriate reserve for both reported claims and IBNR claims for each policy year. For periods between the actuarial studies, the Company records its accruals based on loss rates provided in the most recent actuarial study.
Revenue Recognition	Revenue Recognition Revenue consists of fees earned from the temporary and permanent placement of healthcare professionals and executives as well as from the Company’s software-as-a-service (SaaS)-based technologies, including its vendor management systems (VMS) and its scheduling software. Revenue from temporary staffing services is recognized as the services are rendered by the healthcare professional. Under the Company’s managed services program arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own pool of healthcare professionals along with those of third-party subcontractors. When the Company uses subcontractors, revenue is recorded net of the related subcontractor’s expense. Revenue from recruitment and permanent placement services is recognized as the services are provided and upon successful placements. The Company’s SaaS-based revenue is recognized ratably over the applicable arrangement’s service period. Fees billed in advance of being earned are recorded as deferred revenue.
Accounts Receivable	Accounts Receivable The Company records accounts receivable at the invoiced amount. Accounts receivable are non-interest bearing. The Company maintains an allowance for doubtful accounts based on the Company’s historical write-off experience and an assessment of its customers’ financial conditions. The Company also maintains a sales allowance to reserve for potential credits issued to customers, which is based on the Company’s historical experience. The Company has not experienced material bad debts or sales adjustments during the past three years.
Concentration of Credit Risk	Concentration of Credit Risk The majority of the Company’s business activity is with hospitals located throughout the United States. Credit is extended based on the evaluation of each entity’s financial condition. The Company’s cash and cash equivalents and restricted cash, cash equivalents and investment accounts are financial instruments that are exposed to concentration of credit risk. The Company maintains most of its cash, cash equivalents and investment balances with high-credit quality and federally insured institutions. However, restricted cash equivalents and investment balances may be invested in a non-federally insured money market account and commercial paper.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period the changes are enacted. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making this assessment. The Company recognizes the effect of income tax positions only if it is more likely than not that such positions will be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of the Company’s cash equivalents and restricted cash equivalents and investments approximate their respective fair values due to the short-term nature and liquidity of these financial instruments. The carrying amounts of the Company’s Notes (as defined in Note (3) below), Term Loans and Revolver (as defined in Note (8) below) approximate their fair values. As it relates to the Term Loans and Revolver, the Company amended its credit facilities in January 2016 to increase the capacity of the Revolver and to secure an additional term loan, and the variable interest rate under the Revolver and the Term Loans (LIBOR plus 1.50% to 2.25% or a base rate plus a spread of 0.50% to 1.25%, at the Company’s option) has remained unchanged since the amendment. As it relates to the Notes issued in October 2016, they have a fixed rate of 5.125% and there have been no changes in available rates for similar debt since the date of issuance. See Note (8), “Notes Payable and Credit Agreement,” for additional information. The fair value of the long-term portion of the Company’s insurance accruals cannot be estimated because the Company cannot reasonably determine the timing of future payments.
Share-Based Compensation	Share-Based Compensation The Company accounts for its share-based employee compensation plans by expensing the estimated fair value of share-based awards on a straight-line basis over the requisite employee service period, which is the vesting period. Restricted stock units (“RSUs”) typically vest at the end of a three-year vesting period, however, 33% of the awards may vest on the 13th month anniversary of the grant date and 34% on the second anniversary of the grant date if certain performance targets are met. Share-based compensation cost of RSUs is measured by the market value of the Company’s common stock on the date of grant, and the Company records share-based compensation expense only for those awards that are expected to vest. Performance restricted stock units (“PRSUs”) primarily consist of PRSUs that contain a performance condition dependent on the Company’s adjusted EBITDA margin during the third year of the three-year vesting period, with a range of 0% to 175% of the target amount granted to be issued under the award. Share-based compensation cost for these PRSUs is measured by the market value of the Company’s common stock on the date of grant, and the amount recognized is adjusted for estimated achievement of the performance conditions. A limited amount of PRSUs contain a market condition dependent upon the Company’s relative and absolute total shareholder return over a three-year period, with a range of 0% to 175% of the target amount granted to be issued under the award. Share-based compensation cost for these PRSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the performance conditions.
Segment Information	Segment Information The Company’s operating segments are identified in the same manner as they are reported internally and used by the Company’s chief operating decision maker for the purpose of evaluating performance and allocating resources. Effective as of January 1, 2016, the Company modified its reportable segments. The Company previously utilized three reportable segments, which it identified as follows: (1) nurse and allied healthcare staffing, (2) locum tenens staffing, and (3) physician permanent placement services. In light of the Company’s acquisitions over the past several years as well as its transition to a provider of healthcare workforce solutions, the Company’s management renamed its three reportable segments and also placed several of its business lines that were in the nurse and allied healthcare staffing segment into a different segment to better reflect how the business is evaluated by the chief operating decision maker. As of January 1, 2016, the Company began to disclose the following three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. The nurse and allied solutions segment consists of the Company’s nurse, allied, local and labor disruption and rapid response staffing businesses. The locum tenens solutions segment consists of the Company’s locum tenens staffing business. The other workforce solutions segment consists of the following Company businesses (i) physician permanent placement services, (ii) healthcare interim leadership staffing and executive search services, (iii) vendor management systems, (iv) recruitment process outsourcing, (v) education, (vi) medical coding and related consulting, and (vii) workforce optimization services. The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.
Reclassifications	Reclassifications Certain reclassifications have been made to certain of the prior years’ notes to the consolidated financial statements to conform to the current year presentation.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU 2015-05, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement.” This standard provides guidance about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the software license element of the arrangement should be accounted for by the customer consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company adopted this pronouncement prospectively beginning January 1, 2016, and the adoption did not have a material effect on the Company’s consolidated financial statements. In September 2015, the FASB issued ASU 2015-16, “Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments.” This standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The standard requires that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The standard also requires an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The Company adopted this pronouncement prospectively beginning January 1, 2016, and the adoption did not have a material effect on the Company’s consolidated financial statements.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Computation of basic and diluted net income (loss) per common share

The following table sets forth the computation of basic and diluted net income per common share for the years ended December 31, 2016, 2015 and 2014, respectively:



	Years Ended December 31,
	2016		2015		2014
Net income	$	105,838	$	81,891	$	33,217

Net income per common share - basic	$	2.21	$	1.72	$	0.71
Net income per common share - diluted	2.15		1.68		0.69

Weighted average common shares outstanding - basic	47,946		47,525		46,504
Plus dilutive effect of potential common shares	1,321		1,318		1,582
Weighted average common shares outstanding - diluted	49,267		48,843		48,086

Schedule of reconciliation of revenue and segment operating income by reportable segment to consolidated results



	Years Ended December 31,
	2016		2015		2014
Revenue
Nurse and allied solutions	$	1,185,095	$	953,253	$	674,055
Locum tenens solutions	424,242		385,091		296,166
Other workforce solutions	292,888		124,721		65,806
	$	1,902,225	$	1,463,065	$	1,036,027
Segment operating income
Nurse and allied solutions	$	161,779	$	123,969	$	82,498
Locum tenens solutions	58,757		48,011		30,985
Other workforce solutions	77,450		40,390		14,566
	297,986		212,370		128,049
Unallocated corporate overhead	65,335		52,254		36,996
Depreciation and amortization	29,620		20,953		15,993
Share-based compensation	11,399		10,284		7,157
Interest expense, net (including loss on debt extinguishment of $3,113 for the year ended December 31, 2014), and other	15,465		7,790		9,237
Income before income taxes	$	176,167	$	121,089	$	58,666

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The following table summarizes the fair value and useful life of each intangible asset acquired:



		Fair Value		Useful Life
				(in years)
Identifiable intangible assets
	Tradenames and Trademarks	$	26,300	20
	Customer Relationships	25,700		12
	Staffing Database	13,000		10
	Non-Compete Agreements	900		5
		$	65,900

Summary of Fair Value and Useful Life of Each Intangible Asset Acquired

The following table summarizes the fair value and useful life of each intangible asset acquired:



		Fair Value		Useful Life
				(in years)
Identifiable intangible assets
	Tradenames and Trademarks	$	8,100	3 - 15
	Customer Relationships	17,600		10 - 15
	Staffing Database	2,600		5
	Acquired Technologies	1,700		8
	Non-Compete Agreements	219		2
		$	30,219

Business Acquisition, Pro Forma Information



	Year Ended December 31,
(Unaudited)	2015
Revenue	$	1,556,729
Income from operations	$	132,023
Net income	$	80,114
Net income per common share:
Basic	$	1.69
Diluted	$	1.64

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of financial assets and liabilities measured at fair value on recurring basis



	Fair Value Measurements as of December 31, 2016
Assets (Liabilities)	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	4,627		$	4,627	$	—	$	—
Commercial paper	25,610			—		25,610		—
Interest rate swap asset	24			—		24		—
Acquisition contingent consideration liabilities	(6,816		)	—		—		(6,816		)



	Fair Value Measurements as of December 31, 2015
Assets (Liabilities)	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	5,627		$	5,627	$	—	$	—
Interest rate swap asset	165			—		165		—
Acquisition contingent consideration liabilities	(3,770		)	—		—		(3,770		)

Fair value of contingent consideration liabilities

The following table sets forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:



	Years Ended December 31,
	2016			2015
Balance as of January 1,	$	(3,770	)	$	(1,400	)
Contingent consideration earn-out liability from TFS acquisition on September 15, 2015	—			(2,700		)
Settlement of TFS earn-out for year ended December 31, 2015	1,000			—
Contingent consideration earn-out liability from HSG acquisition on January 11, 2016	(3,590		)	—
Change in fair value of contingent consideration earn-out liability from Avantas acquisition	660			740
Change in fair value of contingent consideration earn-out liability from TFS acquisition	(890		)	(410		)
Change in fair value of contingent consideration earn-out liability from HSG acquisition	(226		)	—
Contingent consideration earn-out liability from Peak acquisition on June 3, 2016	(480		)	—
Change in fair value of contingent consideration earn-out liability from Peak acquisition	480			—
Balance as of December 31,	$	(6,816	)	$	(3,770	)

Goodwill and Identifiable Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Acquired Intangible Assets by Major Class

As of December 31, 2016 and 2015, the Company had the following acquired intangible assets:



	As of December 31, 2016							As of December 31, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangible assets subject to amortization:
Staffing databases	$	19,826	$	(5,633	)	$	14,193	$	6,333	$	(3,592	)	$	2,741
Customer relationships	136,759		(50,309		)	86,450		96,829		(40,076		)	56,753
Tradenames and trademarks	61,369		(12,139		)	49,230		26,853		(7,718		)	19,135
Non-compete agreements	1,697		(678		)	1,019		572		(276		)	296
Acquired technology	8,730		(3,298		)	5,432		8,730		(2,085		)	6,645
	$	228,381	$	(72,057	)	$	156,324	$	139,317	$	(53,747	)	$	85,570

Intangible assets not subject to amortization: tradenames and trademarks						$	89,400						$	89,400
						$	245,724						$	174,970

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Based on the current amount of intangibles subject to amortization, the estimated amortization expense as of December 31, 2016 is as follows:



	Amount
Year ending December 31, 2017	$	18,628
Year ending December 31, 2018	17,555
Year ending December 31, 2019	16,827
Year ending December 31, 2020	13,889
Year ending December 31, 2021	11,899
Thereafter	77,526
	$	156,324

Schedule of Goodwill

The following table summarizes the activity related to the carrying value of goodwill by reportable segment:



	Nurse and Allied Solutions		Locum Tenens Solutions		Other Workforce Solutions		Total
Balance, January 1, 2015	$	73,127	$	14,502	$	66,758	$	154,387
Goodwill adjustment for Avantas acquisition	—		—		165		165
Goodwill from OH acquisition	22,182		5,241		15,210		42,633
Goodwill from TFS acquisition	—		—		4,228		4,228
Goodwill from Millican acquisition	—		—		3,366		3,366
Balance, December 31, 2015	95,309		19,743		89,727		204,779
Goodwill from BES acquisition	—		—		91,127		91,127
Goodwill from HSG acquisition	8,147		—		—		8,147
Goodwill from Peak acquisition	—		—		36,827		36,827
Goodwill adjustment for Onward acquisition	850		—		—		850
Goodwill adjustment for TFS acquisition	—		—		24		24
Balance, December 31, 2016	$	104,306	$	19,743	$	217,705	$	341,754
Accumulated impairment loss as of December 31, 2015 and 2016	$	154,444	$	53,940	$	6,555	$	214,939

Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2016

Balance Sheet Related Disclosures [Abstract]

Consolidated balance sheet details

The consolidated balance sheets detail is as follows as of December 31, 2016 and 2015:



	As of December 31,
	2016			2015
Other current assets:
Restricted cash	20,271			11,995
Income taxes receivable	361			3,687
Other	13,975			8,041
Other current assets	$	34,607		$	23,723

Fixed assets:
Furniture and equipment	$	25,582		$	23,380
Technology and software	112,405			97,962
Leasehold improvements	6,832			5,472
	144,819			126,814
Accumulated depreciation	(84,865		)	(76,680		)
Fixed assets, net	$	59,954		$	50,134

Accounts payable and accrued expenses:
Trade accounts payable	$	33,392		$	28,761
Subcontractor payable	51,973			56,177
Accrued expenses	37,251			24,502
Professional liability reserve	10,254			7,962
Other	4,642			1,420
Accounts payable and accrued expenses	$	137,512		$	118,822

Accrued compensation and benefits:
Accrued payroll	$	30,917		$	21,058
Accrued bonuses and commissions	26,992			24,476
Accrued travel expense	2,972			2,740
Accrued health insurance reserve	3,189			3,225
Accrued workers compensation reserve	8,406			7,701
Deferred compensation	32,690			23,044
Other	2,827			1,457
Accrued compensation and benefits	$	107,993		$	83,701

Other current liabilities:
Acquisition related liabilities	6,921			3,485
Other	9,690			1,889
Other current liabilities	$	16,611		$	5,374

Other long-term liabilities:
Workers compensation reserve	$	18,708		$	16,899
Professional liability reserve	37,338			37,369
Deferred rent	13,274			11,826
Unrecognized tax benefits	8,464			8,081
Other	4,312			3,959
Other long-term liabilities	$	82,096		$	78,134

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of provision for income taxes from continuing operations

The provision for income taxes from operations for the years ended December 31, 2016, 2015 and 2014 consists of the following:



	Years Ended December 31,
	2016			2015		2014
Current income taxes:
Federal	$	68,312		$	22,552	$	10,787
State	11,441			3,969		2,883
Total	79,753			26,521		13,670
Deferred income taxes:
Federal	(9,115		)	8,896		10,430
State	(309		)	3,781		1,349
Total	(9,424		)	12,677		11,779
Provision for income taxes from operations	$	70,329		$	39,198	$	25,449

Total income tax expense for the years ended December 31, 2016, 2015 and 2014 was allocated as follows:



	Years Ended December 31,
	2016			2015			2014
Provision for income taxes from operations	$	70,329		$	39,198		$	25,449
Shareholders’ equity, for compensation expense for tax purposes in excess of amounts recognized for financial reporting purposes	(3,144		)	(7,176		)	(978		)
	$	67,185		$	32,022		$	24,471

Schedule of income tax reconciliation



	Years Ended December 31,
	2016			2015			2014
Tax expense at federal statutory rate	$	61,658		$	42,381		$	20,533
State taxes, net of federal benefit	7,597			5,260			2,551
Non-deductible expenses	3,656			3,505			1,816
Unrecognized tax benefit	379			(11,464		)	971
Other, net	(2,961		)	(484		)	(422		)
Income tax expense from operations	$	70,329		$	39,198		$	25,449

Schedule of deferred tax assets and liabilities



	Years Ended December 31,
	2016			2015
Deferred tax assets:
Stock compensation	$	11,954		$	10,170
Deferred compensation	13,079			9,153
Accrued expenses	35,499			24,932
Deferred rent	5,492			4,885
Net operating losses	5,756			8,809
Other	6,576			4,872
Total deferred tax assets	$	78,356		$	62,821
Deferred tax liabilities:
Intangibles	$	(78,201	)	$	(67,574	)
Fixed assets	(18,847		)	(15,155		)
Other	(2,545		)	(1,480		)
Total deferred tax liabilities	$	(99,593	)	$	(84,209	)
Valuation allowance	$	(183	)	$	(1,043	)
Net deferred tax liabilities	$	(21,420	)	$	(22,431	)

Schedule of unrecognized tax benefits

A summary of the changes in the amount of unrecognized tax benefits (excluding interest and penalties) for 2016, 2015 and 2014 is as follows:



	2016			2015			2014
Beginning balance of unrecognized tax benefits	$	6,537		$	22,890		$	22,573
Additions based on tax positions related to the current year	—			—			317
Additions based on tax positions of prior years	868			395			—
Reductions due to lapse of applicable statute of limitation	(563		)	(214		)	—
Settlements	—			(16,534		)	—
Ending balance of unrecognized tax benefits	$	6,842		$	6,537		$	22,890

Notes Payable and Credit Agreement (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Schedule of outstanding debt

Outstanding debt balances as of December 31, 2016 and 2015 consisted of the following:



	As of December 31,
	2016			2015
Revolver	$	—		$	82,500
Original Term Loan	—			136,875
Second Term Loan	44,063			—
Notes	325,000			—
Total debt outstanding	369,063			219,375
Less unamortized discount	(6,121		)	(885		)
Less current portion of notes payable and Revolver	(3,750		)	(37,500		)
Long-term portion of notes payable and Revolver	$	359,192		$	180,990

Schedule of annual principal maturities

Annual principal maturities of the Second Term Loan and the Notes as of December 31, 2016 are as follows:



Year ending December 31, 2017	$	3,750
Year ending December 31, 2018	3,750
Year ending December 31, 2019	3,750
Year ending December 31, 2020	3,750
Year ending December 31, 2021	29,063
Thereafter	325,000
	$	369,063

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of RSU and PRSU activity for non-vested awards

The following table summarizes RSU and PRSU activity for non-vested awards for the years ended December 31, 2016, 2015 and 2014:



	Number of Shares		Weighted Average Grant Date Fair Value per Share
Unvested at January 1, 2014	1,637		$	9.73
Granted—RSUs	361		$	13.76
Granted—PRSUs (1)	535		$	14.97
Vested	(838	)	$	8.63
Canceled/forfeited/expired	(120	)	$	12.16
Unvested at December 31, 2014	1,575		$	11.95
Granted—RSUs	203		$	22.43
Granted—PRSUs (1)	616		$	13.58
Vested	(1,081	)	$	9.13
Canceled/forfeited/expired	(76	)	$	15.45
Unvested at December 31, 2015	1,237		$	16.73
Granted—RSUs	180		$	32.65
Granted—PRSUs (1)	361		$	20.88
Vested	(641	)	$	14.90
Canceled/forfeited/expired	(62	)	$	22.57
Unvested at December 31, 2016	1,075		$	22.14

(1) PRSUs granted included both the PRSUs granted during the year at the target amount and the additional shares of prior period granted PRSUs vested during the year in excess of the target shares.

Schedule of stock option and SAR activity

A summary of stock option and SAR activity under the Stock Option Plan and the Equity Plan and Other Plans are as follows:



	Stock Option Plan				Equity Plan and Other Plans
	Number Outstanding		Weighted- Average Exercise Price per Share		Number Outstanding		Weighted- Average Exercise Price per Share
Outstanding at December 31, 2013	589		$	14.92	1,096		$	10.78
Granted	—		$	—	—		$	—
Exercised	(117	)	$	14.86	(142	)	$	11.53
Canceled/forfeited/expired	(227	)	$	14.94	(6	)	$	19.69
Outstanding at December 31, 2014	245		$	14.93	948		$	10.61
Granted	—		$	—	—		$	—
Exercised	(245	)	$	14.93	(615	)	$	10.79
Canceled/forfeited/expired	—		$	—	(1	)	$	24.95
Outstanding at December 31, 2015	—		$	—	332		$	10.26
Granted	—		$	—	—		$	—
Exercised	—		$	—	(44	)	$	13.69
Canceled/forfeited/expired	—		$	—	(2	)	$	18.03
Outstanding at December 31, 2016	—		$	—	286		$	9.67
Vested and expected to vest at December 31, 2016	—		$	—	286		$	9.67
Exercisable at December 31, 2016	—		$	—	286		$	9.67

Schedule of share-based compensation expense

Total share-based compensation expense for the years ended December 31, 2016, 2015 and 2014 was as follows:



	Years Ended December 31,
	2016			2015			2014
Share-based employee compensation, before tax	$	11,399		$	10,284		$	7,157
Related income tax benefits	(4,423		)	(3,990		)	(2,783		)
Share-based employee compensation, net of tax	$	6,976		$	6,294		$	4,374

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments

Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) as of December 31, 2016 are as follows:



	Operating Leases
Years ending December 31,
2017	$	17,194
2018	17,037
2019	16,400
2020	15,886
2021	16,019
Thereafter	82,675
Total minimum lease payments	$	165,211

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information



	Year Ended December 31, 2016
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(In thousands, except per share data)
Revenue	$	468,002	$	473,729	$	472,636	$	487,858	$	1,902,225
Gross profit	$	151,898	$	154,753	$	154,467	$	158,606	$	619,724
Net income	$	25,869	$	26,322	$	27,296	$	26,351	$	105,838
Net income per share from:
Basic	$	0.54	$	0.55	$	0.57	$	0.55	$	2.21
Diluted	$	0.53	$	0.53	$	0.55	$	0.54	$	2.15



	Year Ended December 31, 2015
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(In thousands, except per share data)
Revenue	$	327,510	$	350,144	$	382,859	$	402,552	$	1,463,065
Gross profit	$	101,432	$	110,118	$	126,009	$	131,804	$	469,363
Net income	$	12,209	$	15,870	$	33,647	$	20,165	$	81,891
Net income per share from:
Basic	$	0.26	$	0.33	$	0.71	$	0.42	$	1.72
Diluted	$	0.25	$	0.32	$	0.69	$	0.41	$	1.68

Summary of Significant Accounting Policies - Fixed Assets (Details)	12 Months Ended
	Dec. 31, 2016
Furniture, Equipment and Software \| Minimum
Property, Plant and Equipment [Line Items]
Fixed assets, useful life	3 years
Furniture, Equipment and Software \| Maximum
Property, Plant and Equipment [Line Items]
Fixed assets, useful life	10 years
Software Development \| Minimum
Property, Plant and Equipment [Line Items]
Fixed assets, useful life	3 years
Software Development \| Maximum
Property, Plant and Equipment [Line Items]
Fixed assets, useful life	10 years

Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Concentration Risk [Line Items]
Restricted cash, cash equivalents and investments	$ 31,287	$ 27,352
Healthcare System \| Consolidated Revenue \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage	11.00%	11.00%	10.00%

Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2016	Dec. 31, 2016	Oct. 03, 2016
Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Interest rate		0.00%
Term Loan \| Line of Credit
Debt Instrument [Line Items]
Interest rate		2.50%
Minimum \| Revolving Credit Facility \| Line of Credit \| LIBOR
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	1.50%	1.50%
Minimum \| Revolving Credit Facility \| Line of Credit \| Base Rate
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	0.50%	0.50%
Minimum \| Term Loan \| Line of Credit \| LIBOR
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	1.50%	1.50%
Minimum \| Term Loan \| Line of Credit \| Base Rate
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	0.50%	0.50%
Maximum \| Revolving Credit Facility \| Line of Credit \| LIBOR
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	2.25%	2.25%
Maximum \| Revolving Credit Facility \| Line of Credit \| Base Rate
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	1.25%	1.25%
Maximum \| Term Loan \| Line of Credit \| LIBOR
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	2.25%	2.25%
Maximum \| Term Loan \| Line of Credit \| Base Rate
Debt Instrument [Line Items]
Interest rates spread over LIBOR and Base rate	1.25%	1.25%
5.125% Senior Notes due 2024 \| Senior Notes
Debt Instrument [Line Items]
Interest rate		5.125%	5.125%

Summary of Significant Accounting Policies - Share-Based Compensation (Details)	12 Months Ended
	Dec. 31, 2016
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Shares, EBITDA-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for relative and absolute shareholder return	3 years
Performance Shares, Shareholder Return-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for relative and absolute shareholder return	3 years
Minimum \| Performance Shares, EBITDA-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of target amount granted to be issued	0.00%
Minimum \| Performance Shares, Shareholder Return-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of target amount granted to be issued	0.00%
Maximum \| Performance Shares, EBITDA-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of target amount granted to be issued	175.00%
Maximum \| Performance Shares, Shareholder Return-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of target amount granted to be issued	175.00%
Vesting Period, Thirteen Month Aniversary of Grant Date \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.00%
Vesting anniversary term	13 months
Vesting Period, Second Anniversary of Grant Date \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	34.00%
Vesting anniversary term	2 years

Summary of Significant Accounting Policies - Net income per common share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Computation of Basic and Diluted Net Income Per Common Share [Abstract]
Net income	$ 26,351	$ 27,296	$ 26,322	$ 25,869	$ 20,165	$ 33,647	$ 15,870	$ 12,209	$ 105,838	$ 81,891	$ 33,217
Net income per common share - basic (in dollars per share)	$ 0.55	$ 0.57	$ 0.55	$ 0.54	$ 0.42	$ 0.71	$ 0.33	$ 0.26	$ 2.21	$ 1.72	$ 0.71
Net income per common share - diluted (in dollars per share)	$ 0.54	$ 0.55	$ 0.53	$ 0.53	$ 0.41	$ 0.69	$ 0.32	$ 0.25	$ 2.15	$ 1.68	$ 0.69
Weighted average common shares outstanding - basic (shares)									47,946	47,525	46,504
Plus dilutive effect of potential common shares (shares)									1,321	1,318	1,582
Weighted average common shares outstanding - diluted (shares)									49,267	48,843	48,086
Stock Compensation Plan
Class of Stock [Line Items]
Common stock excluded from calculation of EPS (shares)									16	9	298

Summary of Significant Accounting Policies - Segment (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) segment	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Accounting Policies [Abstract]
Number of reportable segments \| segment									3
Segment Reporting Information, Profit (Loss) [Abstract]
Revenue	$ 487,858	$ 472,636	$ 473,729	$ 468,002	$ 402,552	$ 382,859	$ 350,144	$ 327,510	$ 1,902,225	$ 1,463,065	$ 1,036,027
Operating income									191,632	128,879	67,903
Depreciation and amortization									29,620	20,953	15,993
Share-based compensation									11,399	10,284	7,157
Interest expense, net (including loss on debt extinguishment of $3,113 for the year ended December 31, 2014), and other									15,465	7,790	9,237
Loss on extinguishment									0	0	(3,113)
Income before income taxes									176,167	121,089	58,666
Operating Segments
Segment Reporting Information, Profit (Loss) [Abstract]
Revenue									1,902,225	1,463,065	1,036,027
Operating income									297,986	212,370	128,049
Operating Segments \| Nurse and Allied Solutions
Segment Reporting Information, Profit (Loss) [Abstract]
Revenue									1,185,095	953,253	674,055
Operating income									161,779	123,969	82,498
Operating Segments \| Locum Tenens Solutions
Segment Reporting Information, Profit (Loss) [Abstract]
Revenue									424,242	385,091	296,166
Operating income									58,757	48,011	30,985
Operating Segments \| Other Workforce Solutions
Segment Reporting Information, Profit (Loss) [Abstract]
Revenue									292,888	124,721	65,806
Operating income									77,450	40,390	14,566
Corporate, Non-Segment
Segment Reporting Information, Profit (Loss) [Abstract]
Unallocated corporate overhead									$ 65,335	$ 52,254	$ 36,996

Business Combinations (Details)												3 Months Ended			12 Months Ended			36 Months Ended
Business Combinations (Details)	Dec. 31, 2017 USD ($)	Sep. 15, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 15, 2016 USD ($)	Jun. 03, 2016 USD ($)	Jan. 11, 2016 USD ($)	Jan. 04, 2016 USD ($)	Oct. 05, 2015 USD ($)	Sep. 15, 2015 USD ($)	Jan. 07, 2015 USD ($) subsidiary	Dec. 22, 2014 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2016 USD ($) aquisition
Business Combination, Description
Number of acquisitions \| aquisition																		7
Additional cash paid for working capital adjustment settlement															$ 1,848,000	$ 990,000	$ 0
Goodwill			$ 341,754,000									$ 341,754,000			341,754,000	204,779,000	154,387,000	$ 341,754,000
Other Workforce Solutions
Business Combination, Description
Goodwill			217,705,000									217,705,000			217,705,000	89,727,000	66,758,000	217,705,000
Nurse and Allied Solutions
Business Combination, Description
Goodwill			104,306,000									104,306,000			104,306,000	95,309,000	73,127,000	104,306,000
Locum Tenens Solutions
Business Combination, Description
Goodwill			19,743,000									19,743,000			$ 19,743,000	19,743,000	$ 14,502,000	$ 19,743,000
Peak Provider Solutions Acquisition
Business Combination, Description
Purchase price of the acquisition					$ 52,400,000
Cash consideration					51,645,000
Contingent earn-out based on future operating performance (up to)					3,000,000
Contingent earn-out					480,000
Additional cash paid for working capital adjustment settlement													$ 275,000
Fair value of tangible assets acquired					5,658,000
Liabilities assumed					9,305,000
Identified intangible assets					$ 19,220,000
Weighted average useful life of intangible assets					13 years
Peak Provider Solutions Acquisition \| Other Workforce Solutions
Business Combination, Description
Goodwill					$ 36,827,000
Peak Provider Solutions Acquisition \| Tradenames and Trademarks
Business Combination, Description
Identified intangible assets					7,600,000
Peak Provider Solutions Acquisition \| Customer Relationships
Business Combination, Description
Identified intangible assets					11,500,000
Peak Provider Solutions Acquisition \| Scenario, Previously Reported
Business Combination, Description
Purchase price of the acquisition					$ 52,125,000
HealthSource Global Staffing
Business Combination, Description
Purchase price of the acquisition						$ 8,219,000
Cash consideration						2,799,000
Contingent earn-out based on future operating performance (up to)						4,000,000
Contingent earn-out						3,590,000
Fair value of tangible assets acquired						1,025,000
Liabilities assumed						4,897,000
Identified intangible assets						$ 3,944,000
Weighted average useful life of intangible assets						8 years
Cash holdback for potential claims						$ 2,122,000
Working capital settlement													$ 292,000
HealthSource Global Staffing \| Nurse and Allied Solutions
Business Combination, Description
Goodwill						8,147,000
HealthSource Global Staffing \| Earn-Out Payment, Payable in 2017 Based on Results in 2016
Business Combination, Description
Contingent earn-out based on future operating performance (up to)						2,000,000
HealthSource Global Staffing \| Earn-Out Payment, Payable in 2018 Based on Results in 2017
Business Combination, Description
Contingent earn-out based on future operating performance (up to)						2,000,000
HealthSource Global Staffing \| Scenario, Previously Reported
Business Combination, Description
Purchase price of the acquisition						$ 8,511,000
B.E. Smith Acquisition
Business Combination, Description
Cash consideration							$ 161,708,000
Fair value of tangible assets acquired							11,953,000
Liabilities assumed							7,272,000
Identified intangible assets							$ 65,900,000
Weighted average useful life of intangible assets							15 years
Working capital settlement														$ 524,000
Revenue of acquiree												108,459,000
Income before income taxes of acquiree												$ 16,491,000
B.E. Smith Acquisition \| Other Workforce Solutions
Business Combination, Description
Goodwill							$ 91,127,000
B.E. Smith Acquisition \| Tradenames and Trademarks
Business Combination, Description
Identified intangible assets							26,300,000
B.E. Smith Acquisition \| Customer Relationships
Business Combination, Description
Identified intangible assets							25,700,000
B.E. Smith Acquisition \| Scenario, Previously Reported
Business Combination, Description
Cash consideration							162,232,000
Millican Solutions Acquisition
Business Combination, Description
Purchase price of the acquisition								$ 3,985,000
Cash consideration			$ 500,000					2,985,000
Fair value of tangible assets acquired								261,000
Liabilities assumed								287,000
Identified intangible assets								645,000
Goodwill								$ 3,366,000
Weighted average useful life of intangible assets								5 years
Millican Solutions Acquisition \| Scenario, Forecast
Business Combination, Description
Cash consideration	$ 500,000
The First String Healthcare Acquisition
Business Combination, Description
Purchase price of the acquisition									$ 7,653,000
Cash consideration				$ 500,000					4,453,000
Contingent earn-out based on future operating performance (up to)									4,000,000
Contingent earn-out									2,700,000
Fair value of tangible assets acquired									919,000
Liabilities assumed									891,000
Identified intangible assets									3,373,000
Goodwill									$ 4,252,000
Weighted average useful life of intangible assets									7 years
The First String Healthcare Acquisition \| Earn-Out Payment, Payable in 2017 Based on Results in 2016
Business Combination, Description
Contingent earn-out based on future operating performance (up to)									$ 1,000,000
The First String Healthcare Acquisition \| Earn-Out Payment, Payable in 2018 Based on Results in 2017
Business Combination, Description
Contingent earn-out based on future operating performance (up to)									$ 3,000,000
The First String Healthcare Acquisition \| Scenario, Forecast
Business Combination, Description
Cash consideration		$ 1,000,000
Onward Healthcare Acquisition
Business Combination, Description
Cash consideration										$ 76,643,000
Fair value of tangible assets acquired										25,216,000
Liabilities assumed										22,275,000
Identified intangible assets										30,219,000
Goodwill										$ 43,483,000
Weighted average useful life of intangible assets										11 years
Number of subsidiaries acquired \| subsidiary										2
Accounts receivable										$ 21,313,000
Accounts payable and accrued expenses										11,113,000
Onward Healthcare Acquisition \| Other Workforce Solutions
Business Combination, Description
Goodwill										15,210,000
Onward Healthcare Acquisition \| Nurse and Allied Solutions
Business Combination, Description
Goodwill										23,032,000
Onward Healthcare Acquisition \| Locum Tenens Solutions
Business Combination, Description
Goodwill										5,241,000
Onward Healthcare Acquisition \| Tradenames and Trademarks
Business Combination, Description
Identified intangible assets										8,100,000
Onward Healthcare Acquisition \| Customer Relationships
Business Combination, Description
Identified intangible assets										$ 17,600,000
Avantas Acquisition
Business Combination, Description
Purchase price of the acquisition											$ 17,520,000
Cash consideration											14,470,000
Contingent earn-out based on future operating performance (up to)											8,500,000
Contingent earn-out											1,400,000
Additional cash paid for working capital adjustment settlement																$ 165,000
Fair value of tangible assets acquired											1,631,000
Liabilities assumed											3,821,000
Identified intangible assets											9,960,000
Goodwill											$ 9,915,000
Weighted average useful life of intangible assets											14 years
Cash holdback for potential claims											$ 1,650,000
Total purchase price											$ 17,685,000
Line of Credit \| B.E. Smith Acquisition
Business Combination, Description
Maximum borrowing capacity							$ 125,000,000

Business Combinations - Fair Value and Useful Life of Intangible Assets Acquired in B.E. Smith Acquisition (Details) - B.E. Smith Acquisition $ in Thousands	Jan. 04, 2016 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 65,900
Tradenames and Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 26,300
Useful Life	20 years
Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 25,700
Useful Life	12 years
Staffing Database
Acquired Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 13,000
Useful Life	10 years
Non-Compete Agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 900
Useful Life	5 years

Business Combinations - Pro Forma Financial Information (Details) - B.E. Smith Acquisition $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) $ / shares
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenue	$ 1,556,729
Income from operations	132,023
Net income	$ 80,114
Pro forma net income per common share, basic (in dollars per share) \| $ / shares	$ 1.69
Pro forma net income per common share, diluted (in dollars per share) \| $ / shares	$ 1.64

Business Combinations - Fair Value and Useful Life of Intangible Assets Acquired in Onward Health Acquisition (Details) - Onward Healthcare Acquisition $ in Thousands	Jan. 07, 2015 USD ($)
Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 30,219
Tradenames and Trademarks
Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	8,100
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	17,600
Staffing Database
Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 2,600
Useful Life	5 years
Acquired Technologies
Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 1,700
Useful Life	8 years
Non-Compete Agreements
Finite-Lived Intangible Assets [Line Items]
Identified intangible assets	$ 219
Useful Life	2 years
Minimum \| Tradenames and Trademarks
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years
Minimum \| Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Useful Life	10 years
Maximum \| Tradenames and Trademarks
Finite-Lived Intangible Assets [Line Items]
Useful Life	15 years
Maximum \| Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Useful Life	15 years

Derivative Instruments (Details) - USD ($)		12 Months Ended
Derivative Instruments (Details) - USD ($)	Oct. 03, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 30, 2015
Derivative [Line Items]
Interest expense		$ 15,465,000	$ 7,790,000	$ 9,237,000
Interest Rate Swap \| Designated as Hedging Instrument
Derivative [Line Items]
Interest rate swap, face amount	$ 40,000,000				$ 100,000,000
Fixed rate on interest rate swap, percent					0.983%
Interest Rate Swap \| Designated as Hedging Instrument \| Other Assets
Derivative [Line Items]
Fair value of interest rate swap		24,000	$ 165,000
Five Point One Two Five Percent Senior Notes Due Two Thousand Twenty-Four [Member] \| Senior Notes
Derivative [Line Items]
Aggregate principal amount	$ 325,000,000
Interest rate	5.125%
Repayments of long-term debt	$ 138,438,000
Interest expense		$ 238,000

Fair Value Measurement - (Details) - Commercial paper - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commercial paper - total	$ 25,610
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commercial paper - total	25,610	$ 0
Commercial paper - AFS securities	$ 11,152	$ 0

Fair Value Measurement - Financial Assets and (Liabilities) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	$ 4,627	$ 5,627
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	25,610
Interest rate swap asset \| Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	24	165
Acquisition contingent consideration liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	(6,816)	(3,770)
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	4,627	5,627
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Interest rate swap asset \| Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition contingent consideration liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	25,610	0
Significant Other Observable Inputs (Level 2) \| Interest rate swap asset \| Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	24	165
Significant Other Observable Inputs (Level 2) \| Acquisition contingent consideration liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) \| Interest rate swap asset \| Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Acquisition contingent consideration liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) measured at fair value on a recurring basis	$ (6,816)	$ (3,770)

Fair Value Measurement - Reconciliation of Changes in Contingent Consideration Liabilities (Details) - Significant Unobservable Inputs (Level 3) - Acquisition contingent consideration liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ (3,770)	$ (1,400)
Ending balance	(6,816)	(3,770)
The First String Healthcare Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration earn-out liability from acquisition	0	(2,700)
Settlement earn-out	1,000	0
Change in fair value of contingent consideration earn-out liability from acquisition	(890)	(410)
HealthSource Global Staffing
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration earn-out liability from acquisition	(3,590)	0
Change in fair value of contingent consideration earn-out liability from acquisition	(226)	0
Avantas Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in fair value of contingent consideration earn-out liability from acquisition	660	740
Peak Provider Solutions Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration earn-out liability from acquisition	(480)	0
Change in fair value of contingent consideration earn-out liability from acquisition	$ 480	$ 0

Fair Value Measurement - Assets Measured on a Non-Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Impairment charges	$ 0	$ 0	$ 0

Goodwill and Identifiable Intangible Assets - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 228,381	$ 139,317
Accumulated Amortization	(72,057)	(53,747)
Net Carrying Amount	156,324	85,570
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets excluding goodwill	245,724	174,970
Tradenames and Trademarks
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets not subject to amortization: tradenames and trademarks	89,400	89,400
Staffing Database
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	19,826	6,333
Accumulated Amortization	(5,633)	(3,592)
Net Carrying Amount	14,193	2,741
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	136,759	96,829
Accumulated Amortization	(50,309)	(40,076)
Net Carrying Amount	86,450	56,753
Tradenames and Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	61,369	26,853
Accumulated Amortization	(12,139)	(7,718)
Net Carrying Amount	49,230	19,135
Non-Compete Agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,697	572
Accumulated Amortization	(678)	(276)
Net Carrying Amount	1,019	296
Acquired Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	8,730	8,730
Accumulated Amortization	(3,298)	(2,085)
Net Carrying Amount	$ 5,432	$ 6,645

Goodwill and Identifiable Intangible Assets - Estimated Amortization Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Aggregate amortization expense, intangible assets	$ 18,310	$ 11,784
Year ending December 31, 2017	18,628
Year ending December 31, 2018	17,555
Year ending December 31, 2019	16,827
Year ending December 31, 2020	13,889
Year ending December 31, 2021	11,899
Thereafter	77,526
Net Carrying Amount	$ 156,324	$ 85,570

Goodwill and Identifiable Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Beginning Balance	$ 204,779	$ 154,387
Ending Balance	341,754	204,779
Accumulated impairment loss	214,939	214,939
Nurse and Allied Solutions
Goodwill [Roll Forward]
Beginning Balance	95,309	73,127
Ending Balance	104,306	95,309
Accumulated impairment loss	154,444	154,444
Locum Tenens Solutions
Goodwill [Roll Forward]
Beginning Balance	19,743	14,502
Ending Balance	19,743	19,743
Accumulated impairment loss	53,940	53,940
Other Workforce Solutions
Goodwill [Roll Forward]
Beginning Balance	89,727	66,758
Ending Balance	217,705	89,727
Accumulated impairment loss	6,555	6,555
Avantas Acquisition
Goodwill [Roll Forward]
Goodwill adjustment for acquisition		165
Avantas Acquisition \| Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill adjustment for acquisition		165
Onward Healthcare Acquisition
Goodwill [Roll Forward]
Goodwill adjustment for acquisition	850
Goodwill from acquisition		42,633
Onward Healthcare Acquisition \| Nurse and Allied Solutions
Goodwill [Roll Forward]
Goodwill adjustment for acquisition	850
Goodwill from acquisition		22,182
Onward Healthcare Acquisition \| Locum Tenens Solutions
Goodwill [Roll Forward]
Goodwill adjustment for acquisition	0
Goodwill from acquisition		5,241
Onward Healthcare Acquisition \| Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill adjustment for acquisition	0
Goodwill from acquisition		15,210
The First String Healthcare Acquisition
Goodwill [Roll Forward]
Goodwill adjustment for acquisition	24
Goodwill from acquisition		4,228
The First String Healthcare Acquisition \| Locum Tenens Solutions
Goodwill [Roll Forward]
Goodwill from acquisition		0
The First String Healthcare Acquisition \| Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill adjustment for acquisition	24
Goodwill from acquisition		4,228
Millican Solutions Acquisition
Goodwill [Roll Forward]
Goodwill from acquisition		3,366
Millican Solutions Acquisition \| Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill from acquisition		$ 3,366
B.E. Smith Acquisition
Goodwill [Roll Forward]
Goodwill from acquisition	91,127
B.E. Smith Acquisition \| Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill from acquisition	91,127
HealthSource Global Staffing Acquisition
Goodwill [Roll Forward]
Goodwill from acquisition	8,147
HealthSource Global Staffing Acquisition \| Nurse and Allied Solutions
Goodwill [Roll Forward]
Goodwill from acquisition	8,147
Peak Provider Solutions Acquisition
Goodwill [Roll Forward]
Goodwill from acquisition	36,827
Peak Provider Solutions Acquisition \| Other Workforce Solutions
Goodwill [Roll Forward]
Goodwill from acquisition	$ 36,827

Balance Sheet Details (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other current assets:
Restricted cash	$ 20,271	$ 11,995
Income taxes receivable	361	3,687
Other	13,975	8,041
Other current assets	34,607	23,723
Fixed assets:
Furniture and equipment	25,582	23,380
Technology and software	112,405	97,962
Leasehold improvements	6,832	5,472
Fixed assets, gross	144,819	126,814
Accumulated depreciation	(84,865)	(76,680)
Fixed assets, net	59,954	50,134
Accounts payable and accrued expenses:
Trade accounts payable	33,392	28,761
Subcontractor payable	51,973	56,177
Accrued expenses	37,251	24,502
Professional liability reserve	10,254	7,962
Other	4,642	1,420
Accounts payable and accrued expenses	137,512	118,822
Accrued compensation and benefits:
Accrued payroll	30,917	21,058
Accrued bonuses and commissions	26,992	24,476
Accrued travel expense	2,972	2,740
Accrued health insurance reserve	3,189	3,225
Accrued workers compensation reserve	8,406	7,701
Deferred compensation	32,690	23,044
Other	2,827	1,457
Accrued compensation and benefits	107,993	83,701
Other current liabilities:
Acquisition related liabilities	6,921	3,485
Other	9,690	1,889
Other current liabilities	16,611	5,374
Other long-term liabilities:
Workers compensation reserve	18,708	16,899
Professional liability reserve	37,338	37,369
Deferred rent	13,274	11,826
Unrecognized tax benefits	8,464	8,081
Other	4,312	3,959
Other long-term liabilities	$ 82,096	$ 78,134

Income Taxes - Provision (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes - Provision (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current income taxes:
Federal	$ 68,312	$ 22,552	$ 10,787
State	11,441	3,969	2,883
Total	79,753	26,521	13,670
Deferred income taxes:
Federal	(9,115)	8,896	10,430
State	(309)	3,781	1,349
Total	(9,424)	12,677	11,779
Income tax expense from operations	$ 70,329	$ 39,198	$ 25,449

Income Taxes - Income Tax Expense Allocation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Provision for income taxes from operations	$ 70,329	$ 39,198	$ 25,449
Shareholders’ equity, for compensation expense for tax purposes in excess of amounts recognized for financial reporting purposes	(3,144)	(7,176)	(978)
Total income tax expense	$ 67,185	$ 32,022	$ 24,471

Income Taxes - Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal statutory tax rate	35.00%	35.00%	35.00%
Income tax reconciliation
Tax expense at federal statutory rate	$ 61,658	$ 42,381	$ 20,533
State taxes, net of federal benefit	7,597	5,260	2,551
Non-deductible expenses	3,656	3,505	1,816
Unrecognized tax benefit	379	(11,464)	971
Other, net	(2,961)	(484)	(422)
Income tax expense from operations	$ 70,329	$ 39,198	$ 25,449

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets
Stock compensation	$ 11,954	$ 10,170
Deferred compensation	13,079	9,153
Accrued expenses	35,499	24,932
Deferred rent	5,492	4,885
Net operating losses	5,756	8,809
Other	6,576	4,872
Total deferred tax assets	78,356	62,821
Deferred tax liabilities
Intangibles	(78,201)	(67,574)
Fixed assets	(18,847)	(15,155)
Other	(2,545)	(1,480)
Total deferred tax liabilities	(99,593)	(84,209)
Valuation allowance	(183)	(1,043)
Net deferred tax liabilities	(21,420)	(22,431)
Deferred tax benefit	$ (9,424)	$ 12,677	$ 11,779

Income Taxes - Operating Loss Carryforwards (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Federal
Operating Loss Carryforwards
Operating loss carryforwards	$ 13,920
State
Operating Loss Carryforwards
Operating loss carryforwards	$ 16,674

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2019	Sep. 30, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance of unrecognized tax benefits		$ 6,537	$ 22,890	$ 22,573
Additions based on tax positions related to the current year		0	0	317
Additions based on tax positions of prior years		868	395	0
Reductions due to lapse of applicable statute of limitation		(563)	(214)	0
Settlements		0	(16,534)	0
Ending balance of unrecognized tax benefits		6,842	6,537	22,890
Unrecognized tax benefits that would affect the effective tax rate		6,752
Accrued interest and penalties related to uncertain tax positions		1,622	1,544	5,815
Interest and penalties recognized		78	$ (4,272)	$ 1,211
Domestic Tax Authority
Income Tax Contingency [Line Items]
Federal income tax benefit						$ 12,200
State
Income Tax Contingency [Line Items]
Federal income tax benefit		$ 568
Federal \| Domestic Tax Authority
Income Tax Contingency [Line Items]
IRS settlement amount	$ 7,200
Scenario, Forecast \| State
Income Tax Contingency [Line Items]
Federal income tax benefit					$ 1,200

Notes Payable and Credit Agreement (Details)		1 Months Ended		12 Months Ended
Notes Payable and Credit Agreement (Details)	Oct. 03, 2016 USD ($)	Jan. 31, 2016	Apr. 30, 2014 credit_facility	Dec. 31, 2016 USD ($) credit_facility	Dec. 31, 2014 USD ($)	Sep. 19, 2016 USD ($)	Apr. 18, 2014 USD ($)
Line of Credit Facility [Line Items]
Write off of unamortized financing fees and original issue discount					$ 3,113,000
Debt issuance fees capitalized							$ 3,488,000
Line of Credit
Line of Credit Facility [Line Items]
Number of credit facilities \| credit_facility			2	3
Line Of Credit Facility, Potential Future Increase To Maximum Borrowing Capacity						$ 125,000,000
Repayments of long-term debt	$ 138,438,000
Debt issuance fees incurred				$ 632,000
Debt issuance fees capitalized				448,000
Line of Credit \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity				275,000,000
Increase to maximum borrowing capacity				$ 50,000,000
Interest rate				0.00%
Repayments of debt	182,500,000
Line of Credit \| Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Unused fee, percent				0.25%
Letter of credit fee				1.50%
Line of Credit \| Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Unused fee, percent				0.35%
Letter of credit fee				2.25%
Line of Credit \| Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 40,000,000
Debt collateral				10,752,000
Available credit				264,248,000
Line of Credit \| Revolving Credit Facility, Swing Line Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity				20,000,000
Line of Credit \| Term Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 150,000,000
Amortization rate				5.00%
Annual principal payment				$ 3,750,000
Interest rate				2.50%
Repayments of debt	131,250,000
Line of Credit \| Second Term Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 75,000,000
Repayments of debt	$ 7,188,000
Line of Credit \| LIBOR \| Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		1.50%		1.50%
Line of Credit \| LIBOR \| Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		2.25%		2.25%
Line of Credit \| LIBOR \| Term Loan \| Minimum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		1.50%		1.50%
Line of Credit \| LIBOR \| Term Loan \| Maximum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		2.25%		2.25%
Line of Credit \| Base Rate \| Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		0.50%		0.50%
Line of Credit \| Base Rate \| Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		1.25%		1.25%
Line of Credit \| Base Rate \| Term Loan \| Minimum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		0.50%		0.50%
Line of Credit \| Base Rate \| Term Loan \| Maximum
Line of Credit Facility [Line Items]
Interest rates spread over LIBOR and Base rate		1.25%		1.25%
Senior Notes \| 5.125% Senior Notes due 2024
Line of Credit Facility [Line Items]
Interest rate	5.125%			5.125%
Debt issuance fees capitalized	$ 6,113,000
Aggregate principal amount	$ 325,000,000

Notes Payable and Credit Agreement - Schedule of Outstanding Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total debt outstanding	$ 369,063	$ 219,375
Less unamortized discount	(6,121)	(885)
Less current portion of notes payable and Revolver	(3,750)	(37,500)
Long-term portion of notes payable and Revolver	359,192	180,990
Line of Credit \| Notes
Debt Instrument [Line Items]
Total debt outstanding	325,000	0
Revolving Credit Facility \| Line of Credit \| Revolver
Debt Instrument [Line Items]
Total debt outstanding	0	82,500
Term Loan \| Line of Credit \| Original Term Loan
Debt Instrument [Line Items]
Total debt outstanding	0	136,875
Second Term Loan \| Line of Credit \| Second Term Loan
Debt Instrument [Line Items]
Total debt outstanding	$ 44,063	$ 0

Notes Payable and Credit Agreement - Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Maturities of Long-term Debt [Abstract]
Year ending December 31, 2017	$ 3,750
Year ending December 31, 2018	3,750
Year ending December 31, 2019	3,750
Year ending December 31, 2020	3,750
Year ending December 31, 2021	29,063
Thereafter	325,000
Long-term portion of Second Term Loan and the Notes	$ 369,063	$ 219,375

Notes Payable and Credit Agreement - Letters of Credit (Details) - Standby Letters of Credit - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Letters of credit, amount outstanding	$ 15,379	$ 15,788
Debt collateral	$ 4,627

Retirement Plans - 401(k) Retirement Savings Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employer contributions, net of forfeitures	$ 5,010	$ 1,618	$ 544

Retirement Plans - Deferred Compensation Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Cash surrender value of life insurance	$ 32,190	$ 23,005
Key Executives and Key Employees
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Service vesting period	5 years
Maximum percent of base salary deferrable	80.00%
Maximum percent of bonus deferrable	90.00%
Maximum percent of vested RSUs and PRSUs deferrable	100.00%
Employer contributions	$ 3,032	$ 974	$ 595

Capital Stock (Details) - USD ($)	3 Months Ended
Capital Stock (Details) - USD ($)	Dec. 31, 2016	Nov. 01, 2016	Dec. 31, 2015
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock total shares including Series A	10,000,000		10,000,000
Preferred stock, par value (in dollars per share)	$ 0.01		$ 0.01
Preferred stock, shares outstanding	0		0
Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]
Stock repurchase program, authorized amount		$ 150,000,000
Treasury stock acquired (shares)	443,000
Treasury stock acquired (in dollars per share)	$ 29.88
Aggregate purchase price of treasury stock	$ 13,261,000

Share-Based Compensation - Textual (Details) - USD ($) $ in Thousands					12 Months Ended
	Apr. 18, 2012	Apr. 09, 2009	Apr. 18, 2007	Apr. 12, 2006	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2006
Stock Options and Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of share-based payment award exercised					$ 877	$ 10,505	$ 770
Total intrinsic value of share-based payment award outstanding and exercisable					8,247	7,013
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost					$ 11,136
Unrecognized compensation cost, weighted average remaining period					1 year 9 months
RSUs and Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value					$ 41,317	$ 38,400
Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock transferred between plans				371,000
Stock Option Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance					4,178,000
Stock option plan - equity awards outstanding (shares)					0	0	245,000		589,000
Stock Option Plan \| Stock Options and Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity awards reserved for future issuance (shares)					0
Equity Plan \| Stock Options and Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance										723,000
Number of equity awards reserved for future issuance (shares)					1,933,000	2,128,000
Contractual life of stock options and SARs					10 years
Additional number of shares authorized	2,400,000	1,850,000	3,000,000
2014 Employee Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance								200,000
Number of shares of common stock available for future grants					200,000

Share-Based Compensation - Restricted Stock Units (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Shares
Unvested, Beginning Balance (shares)	1,237	1,575	1,637
Vested (shares)	(641)	(1,081)	(838)
Canceled/forfeited/expired (shares)	(62)	(76)	(120)
Unvested, Ending Balance (shares)	1,075	1,237	1,575
Weighted Average Grant Date Fair Value per Share
Unvested, Beginning Balance (in dollars per share)	$ 16.73	$ 11.95	$ 9.73
Vested (in dollars per share)	14.90	9.13	8.63
Canceled/forfeited/expired (in dollars per share)	22.57	15.45	12.16
Unvested, Ending Balance (in dollars per share)	$ 22.14	$ 16.73	$ 11.95
Restricted Stock Units (RSUs)
Number of Shares
Granted (shares)	180	203	361
Weighted Average Grant Date Fair Value per Share
Granted (in dollars per share)	$ 32.65	$ 22.43	$ 13.76
Performance Restricted Stock Units (PRSUs)
Number of Shares
Granted (shares)	361	616	535
Weighted Average Grant Date Fair Value per Share
Granted (in dollars per share)	$ 20.88	$ 13.58	$ 14.97

Share-Based Compensation - Summary of Stock Option and SAR Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
RSUs and Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value	$ 41,317	$ 38,400
Stock Option Plan \| Stock Options
Stock Option Plan, Number Outstanding
Outstanding, Beginning balance (shares)	0	245,000	589,000
Granted (shares)	0	0	0
Exercised (shares)	0	(245,000)	(117,000)
Canceled/forfeited/expired (shares)	0	0	(227,000)
Outstanding, Ending balance (shares)	0	0	245,000
Vested and expected to vest (shares)	0
Exercisable (shares)	0
Stock Option Plan, Weighted-Average Exercise Price per Share
Outstanding, Beginning balance (in dollars per share)	$ 0.00	$ 14.93	$ 14.92
Granted (in dollars per share)	0.00	0.00	0.00
Exercised (in dollars per share)	0.00	14.93	14.86
Canceled/forfeited/expired (in dollars per share)	0.00	0.00	14.94
Outstanding, Ending balance (in dollars per share)	0.00	$ 0.00	$ 14.93
Vested and expected to vest (in dollars per share)	0.00
Exercisable (in dollars per share)	$ 0.00
Equity Plan and Other Plans \| Stock Appreciation Rights (SARs)
Equity Plan and Other Plans, Number Outstanding
Outstanding, Beginning balance (shares)	332,000	948,000	1,096,000
Granted (shares)	0	0	0
Exercised (shares)	(44,000)	(615,000)	(142,000)
Canceled/forfeited/expired (shares)	(2,000)	(1,000)	(6,000)
Outstanding, Ending balance (shares)	286,000	332,000	948,000
Vested and expected to vest (shares)	286,000
Exercisable (shares)	286,000
Equity Plan and Other Plans, Weighted-Average Exercise Price per Share
Outstanding, Beginning balance (in dollars per share)	$ 10.26	$ 10.61	$ 10.78
Granted (in dollars per share)	0.00	0.00	0.00
Exercised (in dollars per share)	13.69	10.79	11.53
Canceled/forfeited/expired (in dollars per share)	18.03	24.95	19.69
Outstanding, Ending balance (in dollars per share)	9.67	$ 10.26	$ 10.61
Vested and expected to vest (in dollars per share)	9.67
Exercisable (in dollars per share)	$ 9.67

Share-Based Compensation - Share Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based employee compensation, before tax	$ 11,399	$ 10,284	$ 7,157
Related income tax benefits	(4,423)	(3,990)	(2,783)
Share-based employee compensation, net of tax	$ 6,976	$ 6,294	$ 4,374

Commitments and Contingencies - Capital and Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leases
2017	$ 17,194
2018	17,037
2019	16,400
2020	15,886
2021	16,019
Thereafter	82,675
Total minimum lease payments	165,211
Rent expense under operating leases for continuing operations	$ 18,793	$ 15,940	$ 14,136

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Selected Quarterly Financial Information [Abstract]
Revenue	$ 487,858	$ 472,636	$ 473,729	$ 468,002	$ 402,552	$ 382,859	$ 350,144	$ 327,510	$ 1,902,225	$ 1,463,065	$ 1,036,027
Gross profit	158,606	154,467	154,753	151,898	131,804	126,009	110,118	101,432	619,724	469,363	316,117
Net income	$ 26,351	$ 27,296	$ 26,322	$ 25,869	$ 20,165	$ 33,647	$ 15,870	$ 12,209	$ 105,838	$ 81,891	$ 33,217
Basic (in dollars per share)	$ 0.55	$ 0.57	$ 0.55	$ 0.54	$ 0.42	$ 0.71	$ 0.33	$ 0.26	$ 2.21	$ 1.72	$ 0.71
Diluted (in dollars per share)	$ 0.54	$ 0.55	$ 0.53	$ 0.53	$ 0.41	$ 0.69	$ 0.32	$ 0.25	$ 2.15	$ 1.68	$ 0.69